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Atherosclerosis and high circulating levels of oxidized low density lipoproteins 
(oxLDL) are considered among the most important risk factors for the occurrence 
and development of cardiovascular disease (CVD). During the atherosclerotic 
lesion repair, phenotypic transition of vascular smooth muscle cells (VSMCs) 
from contractile to synthetic states plays a central role. In this process, enhanced 
proliferation/migration of VSMCs, from the tunica media to the intima, is required 
to sustain blood vessel endothelium integrity, and for inducing vessel wall 
remodeling in response to injury. At the molecular level, the activity of 
electroneutral potassium-chloride cotransporters or KCCs, is necessary to: a) 
allow changes in cell volume (key prerequisites to coordinate cell 
proliferation/migration) and b) sustain normal cardiovascular function. Stimulation 
of the adipokine apelin and its receptor APJ (apelin/APJ) signaling pathway has 
been shown to protect against atherosclerotic lesion formation by lowering blood 
pressure levels and promoting vasodilation. Upon binding to APJ, apelin 
promotes nitric oxide (NO)-mediated vasodilation, and cell proliferation via the 




signaling pathways regulating the KCCs. However, the mechanisms of KCC 
regulation by apelin/APJ remain to be determined. Thus, we hypothesized that 
KCC expression and activity play an important role during VSMCs’ phenotypic 
transition and could be involved in the apelin/APJ cardioprotective effects. In 
addition, it is possible that the apelin-mediated effect on KCC activity could also 
be dependent on factors affecting the transporter, such as, serum, ionic strength, 
osmolality, cell proliferation and migration.  
This hypothesis will be tested using rat aortic VSMCs that were immunologically 
validated by specific markers. KCC activity was measured by atomic absorption 
spectrophotometry using rubidium as a potassium (K+) congener. KCC 
expression and transport activity were characterized with respect to the VSMC 
phenotypes, in the presence or absence of apelin and corresponding inhibitors of 
the signaling pathways, oxLDL and as a function of the various aforementioned 
physiological factors.   
While markers for the contractile VSMC phenotype are well known, they are less 
defined for the early and late synthetic ones. In the present study, we showed a 
decrease in expression levels of cytoskeletal proteins like α-actin, desmin and 
vimentin in late synthetic VSMCs compared to early states suggesting that the 
latter show similar characteristics to the contractile phenotype. In addition, KCC1 
and KCC4 protein expression and overall KCC activity increased in late vs early 
synthetic VSMCs. The ion binding affinity (Km) for late and early synthetic VSMCs 
was similar for K+ whereas it decreased for Cl-. Whether the increase in KCC 




or enhanced membrane trafficking/insertion of de novo synthesized KCC protein 
remains to be studied. Using selective inhibitors, we showed that apelin-
mediated activation of KCCs occurs through the NO/sGC/PKG pathway in 
contractile, and by PI3K/Akt and MAPK dependent pathway(s) in synthetic 
VSMCs. Furthermore, apelin rescued the inhibition of KCC induced by oxLDL in 
contractile VSMCs. We also showed that the apelin-mediated activation of KCCs 
is dependent on extracellular sodium, osmolality, presence of serum in the 
growth media, VSMCs phenotype (contractile vs synthetic), and passage 
number.  Altogether, our results identify apelin/APJ as an important modulator of 
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Cardiovascular disease (CVD) is the leading cause of mortality worldwide (1-3). It 
has been estimated that CVD is responsible for over thirty percent of global 
deaths and billions of dollars are being spent on its prevention and treatment (4). 
CVD includes a number of health problems that affect heart and/or blood vessels 
function. Ischemic heart disease and stroke are among the most predominant 
CVDs. According to the World Health Organization (WHO), they are responsible 
for over 13 million deaths a year (5).  
 
Among the several risk factors that lead to CVD, atherosclerosis (hardening and 
narrowing of the blood vessels) plays a pivotal role (6). In brief, endothelial 
dysfunction, loss of contractility of vascular smooth muscle cells (VSMCs) 
combined with improper handling of low density lipoproteins (LDL) and increased 
oxidative stress, result in luminal narrowing and concomitant inflammatory 
events. In sum, these processes trigger sub-endothelial accumulation of oxidized 
low density lipoproteins (oxLDL), macrophage infiltration and lesion formation 
(foam cell appearance and atherosclerotic plaques) (7) (Figure 1). 
Since damaged endothelium of blood vessels plays a key role in the occurrence 
and developing of atherosclerosis, a brief description of blood vessels’ 






Figure 1. Events leading to atheroscleotic plaque formation. 
Atherosclerosis is the underlying cause of CVD resulting from processes 
involving endothelial dysfunction, accumulation of oxLDL, migration of 
VSMCs, and infiltration of macrophages among others. Figure modified with 




Blood vessels’ architecture  
Blood vessels are located throughout the body, and are hollow tubes that 
circulate blood to different organs. Functional blood vessels require the formation 
of endothelial tubes and recruitment of smooth muscle cells around these 
endothelial cells to form a multilayered vessel wall (9). Structurally, blood vessels 
are mainly composed of three concentric layers also called “tunica”. The 
innermost layer is the “intima”, the middle one is called “media” and the most 
exterior one called “adventitia”. The intima outlines the lumen of the vessel wall. 
This layer is in direct contact with red blood cells and forms a slick surface to 
minimize friction against blood flow.  The normal intima of large arteries, like the 
aorta, has a continuous endothelial monolayer seated on a basement membrane, 
separated from the media by the internal elastic lamina (10). The tunica media 
consists of VSMCs, macrophages, and fibroblasts (11). The media is very elastic 
and primarily composed of VSMCs arranged circumferentially. The muscle 
relaxes to vasodilate and contracts to vasoconstrict the vessel. This allows the 
regulation of blood flow. Outside of the tunica media is the adventitia that is 
separated from the media by the external elastic lamina. The outermost layer, 
adventitia, consists of connective tissue made up of fibroblasts and nerve fibers 
(12). The strong connective tissue supports and strengthens the vessel, 






Figure 2. Composition of vascular wall. Functional blood vessels require 
the formation of endothelial tubes and recruitment of smooth muscle cells 
around these endothelial cells to form a multilayered vessel wall. The tunica 
intima, tunica media, and tunica externa (adventitia), are the three basic 




One important feature of the tunica media is its elasticity. When VSMCs 
relax/shrink, vasodilation is promoted, whereas when they contract/swell, 
vasoconstriction is sustained (13, 14). Regulation of cell volume is necessary to 
coordinate vasoconstriction/vasodilation events in order to sustain vascular tone 
and proper blood flow (Figure 3).   
 
Vascular smooth muscle cells  
VSMCs constitute the major component of the blood vessels’ tunica media. By 
controlling changes in their cell volume; they are responsible for modulating 
vessel luminal diameters and thus vascular tone (Figures 2 and 3).  The 
structural integrity of VSMC is maintained by various components. The plasma 
membrane contains multiple invaginations, called caveola. These caveolae 
enclose molecules essential for the initiation of signal transduction (15). Gap 
junctions in the periphery connect adjacent smooth muscle cells allowing the 
transmission of signals from cell to cell (16). A large portion of cytoplasmic 
volume is taken up by actin and myosin molecules, and the interactions of these 
filaments modulate the contraction of the smooth muscle. In VSMCs, α-actin is 
the prevalent actin filament isoform, a component of the contractile machinery 
(17, 18). Furthermore, intermediate filaments such as desmin and vimentin also 
play a key role in the coordinated relaxation and contraction of VSMCs (19). 
Thus, the coordinated interaction between the contractile machinery and 





Figure 3. VSMCs regulate the vessel luminal diameter. VSMCs are 
elastic in nature and necessary for proper vascular tone 
(vasoconstriction/vasodilation) VSMCs are responsible for controlling the 





VSMCs participate in atherosclerotic lesions due to their remarkable capacity to 
migrate and proliferate. VSMCs uniqueness relies in their two extreme 
phenotypes: contractile and synthetic, with intermediate phenotypes in between 
(20-22). VSMCs undergo phenotypic modulation, especially during vascular 
injury (Figure 1). The contractile phenotype of VSMCs, which is required to allow 
vasodilation and vasoconstriction, is characterized by a robust NO-signaling 
casacade. It consists of the nitric oxide (NO)/soluble guanylate cyclase 
(sGC)/protein kinase G (PKG) pathway involved in vasodilation and 
vasoconstriction (23-25). In contrast, the synthetic phenotype, predominantly 
expressed in diseased blood vessels,  is characterized by an impaired NO 
pathway and overexpression of the mitogen activated protein kinase (MAPK) and 
phosphatidylinositol-3-kinase (PI3K)/protein kinase B/Akt pathways both involved 
in cell proliferation. The differences in expression of protein markers, signaling 
molecules, and rate of proliferation and migration determine the VSMCs 
phenotypes (13). The transition from contractile to synthetic favors vascular 
remodeling and makes VSMCs an important model system to study 
atherosclerosis (23, 26, 27). 
 
Due to their remarkable capacity to migrate, proliferate and differentiate into 
extreme different phenotypic states (contractile and synthetic); VSMCs also play 
an important role in the repairing of atherosclerotic lesions (20-22). When 
atherosclerotic lesions occur, transition from a “contractile” to a “synthetic state” 
facilitates proliferation and cell migration. Failure to switch back to a contractile 




VSMCs involves different protein expression profiles that are required to sustain 
and restore vascular function and cell contractibility (Figure 1). Under normal 
conditions, VSMCs can be found in a quiescent state and proliferate infrequently. 
Contractile VSMCs undergo phenotypic switching to synthetic states in response 
to hypertension, vascular damage, oxLDLs or atherosclerotic lesions (13, 28, 29).  
 
To properly coordinate vasodilation/vasoconstriction events, contractile VSMCs 
rely on exquisite rearrangements of actin and myosin molecules along with 
intermediate filaments such as desmin and vimentin (17, 18).  
 
The nitric oxide/soluble guanylate cyclase/protein kinase G signaling cascade 
(NO/sGC/PKG) is one of the most important regulators of the contractile 
machinery (30). When contractile VSMCs differentiate to synthetic states, 
(NO/sGC/PKG) becomes unresponsive and upregulation of signaling cascades 
involved in cell proliferation and migration takes place (MAPK and 
phosphatidylinositol-3-kinase (PI3K)/protein kinase B/Akt pathways) (13) (Figure 
4). In addition, synthetic VSMCs exhibit high levels of production of extracellular 
matrix proteins needed for vascular remodeling during atherosclerotic injury (23, 





Figure 4. VSMCs phenotypic differentiation.  VSMCs have two extreme 
phenotypes: contractile and synthetic. VSMCs in their contractile state have 
a spindle-like elongated morphology, express contractile proteins and 
regulate vascular tone. The Nitric oxide (NO)/sGC/PKG pathway is highly 
expressed in contractile VSMCs and is responsible for determining the 
vasodilation/vasoconstriction levels. Synthetic VSMCs display a fibroblast 
like morphology, exhibit high expression of extracellular matrix proteins 
(ECM) and are highly proliferative and mobile. PI3K/Akt and Ras/Raf/Erk1/2 
MAPK pathways sustain cell proliferation and migration involved in the 




Given that high plasma levels of low density lipoproteins (LDLs) impair VSMCs’ 
function and vasodilation of blood vessels, a brief discussion of their 
characteristics and their role in CVD will be presented.  
 
Low density lipoproteins 
LDLs are the principal particles to transport cholesterol and fat in the human 
body. They are sphere-like structures (18-25 nm in diameter), made basically of 
phospholipid monolayers and apolipoprotein B-100 (Apo B) (31, 32). The 
hydrophobic core of LDLs is the site where cholesterol molecules are carried. 
During cellular demand for cholesterol, Apo B on the surface of LDLs interacts 
with specific receptors and triggers endocytosis to facilitate uptake and utilization 
of lipids through lysosomal degradation (33). 
 
Studies have shown that high circulating levels of LDL (over 160 mg/dL) facilitate 
cholesterol deposition in the tunica intima which, over time, promotes 
atherosclerotic plaque formation and lumen narrowing (34) (Figure 1). Thus, 




Oxidation of Low Density Lipoproteins  
The oxidation of LDLs is considered one of the major culprits for the progression 
of atherosclerosis and occurrence of CVD (35-37). In brief, oxLDLs accelerate 
various pro-inflammatory and pro-atherogenic pathways (38). When LDLs are 
oxidized, they cannot be recognized by their “normal” LDL-receptors. Thus, in 
order to facilitate oxLDL uptake and its clearance from the tunica media, various 
scavenger receptors such as CD36 and LOX-1 are up-regulated (39, 40).  
 
Reports have shown that there are abundant scavenger receptors in 
macrophages, endothelial cells and VSMCs. These scavenger receptors play a 
crucial role in the uptake of oxLDL. Uncontrolled uptake of oxLDL leads to 
morphology changes (appearance of foam cells: fat laden macrophages and 
VSMCs) (39, 41, 42). Besides changes in morphology, oxLDLs dramatically 
disturb cell function (Figure 5). They support recruitment of monocytes, facilitate 
macrophage infiltration, impair nitric oxide (NO) production/vasodilation and 
promote VSMCs differentiation, proliferation and migration. Altogether, oxLDLs 
profoundly impair normal vascular function and therefore contribute to the 
development of atherosclerotic lesions (39, 40).  
 
As part of the repair mechanisms of atherosclerotic lesions; differentiation and 
migration of VSMCs is of crucial importance (43, 44). Because oxLDLs have 
shown to support the phenotypic transition of VSMCs, a more detailed 







Figure 5. oxLDL atherogenic effects on cell function. oxLDL uptake by 
scavenger receptors expressed in endothelium, VSMCs and macrophages, 






In vitro primary cultures of VSMCs to study atherosclerosis progression 
A time-dependent dynamic phenotyping switch in VSMCs was evident ever since 
they were first isolated and cultured in vitro (Figure 4). At initial stages of 
subculturing (passage # 1 to 4), cultured VSMCs display ribbon-like elongated 
shapes with high resemblance to the cells from intact tissue. Early in vitro 
VSMCs cultures exhibit high density of myosin filaments with close resemblance 
to contractile VSMCs in vivo. After several days in culture, the expression of 
myofilaments decreases, and the cells begin to resemble the “synthetic” cells 
seen during blood vessels’ regeneration and atherosclerotic plaques (45).  
 
In vivo, contractile VSMCs undergo phenotypic switching due to stimuli like 
hypertension, vascular damage, exposure to oxLDLs or atherosclerotic lesions; 
in vitro, the phenotypic status of VSMCs is determined mainly by passage 
number or incubation with certain mitogens or growth factors (e.g., oxLDL, 
PDGF) (21, 22, 46-48). The possibility to obtain and track in vitro the transition of 
VSMCs to synthetic/diseased stages makes the usage of VSMCs extremely 
helpful in obtaining a better understanding of the progression of atherosclerotic 
lesions.  
 
Apelin/APJ cardioprotective role 
Recently, the signaling pathway (apelin/APJ), involving the adipokine apelin and 
its G-protein coupled receptor (APJ), has emerged as a potent regulator of 
cardiovascular function (49-51). Apelin, is generated in vivo as a 77 amino acid 




(Apelin-13,-16,-17,-19 and 36) among which, apelin-13, exhibits the highest 
activity and concentration in the circulatory system (52-54) (Figure 6). 
Additionally, the apelin peptide undergoes posttranslational modification which 
results in the addition of pyroglutamate to the N terminus region producing (pyr1) 
apelin-13 peptide. The pyroglutamation protects the peptide from exopeptidase 
degradation and preserves its biological activity (55). 
 
APJ Receptor 
The Apelin receptor (APJ) is a 7 transmembrane (TM) domain structure that 
belongs to the G-protein coupled receptor (GPCR) family. The receptor is 
expressed in numerous tissues, including heart, lung, liver, kidney, 
gastrointestinal tract, brain, adrenal gland, endothelium and smooth muscle. The 
gene encoding for APJ designated APLNR encodes for a 380-amino acid protein 
and is located on chromosome 11q12 (56, 57). APLNR is evolutionary conserved 
among species (57, 58). The APJ receptor shares 54% of identity in the TM 
region and 30% overall with the angiotensin II (Ang II) receptor, AT1 (56). Even 
though there is high identity between the APJ and AT1 receptors, the Ang II 
molecule does not bind to the APJ receptor (51). 
 
Upon binding to its receptor, apelin-13 triggers a plethora of signaling cascades 
and changes in protein expression that have proven to be beneficial against CVD 
(52). Among its cardio-protective effects, scientific evidence highlights: strong 
anti-hypertensive and anti-atherogenic properties; all of them associated with 




the PI3K/Akt, and c) the mitogen activated protein kinase MAPK signaling 
network  Ras/Raf/Erk (51, 53, 59-63).  
 
Apelin administration antagonizes the hypertensive effect of Ang II in vascular 
complications like atherosclerosis by increasing NO levels (51, 64, 65). Apelin 
also has ionotropic effects by increasing the heart rate and contractility of 
isolated and intact hearts of mice and rat (66, 67). Binding of apelin to APJ 
alleviates hypertension and has a protective effect in ischemic heart disease. 
Several in vivo and in vitro models have revealed a potential role of apelin in 
cardiovascular function, for instance, in knockout mice models for apelin, 
impaired cardiac contractility and occurrence of CVD have been observed (68). 
Studies have shown that apelin acts as a potent angiogenic factor promoting 
proliferation of VSMCs and endothelial cells (69-71). Consistent with its role 
promoting cell proliferation, apelin has proven to suppress via PI3K/Akt apoptotic 
cell death. Both apelin and APJ are needed for cardiovascular development and 
formation of heart morphology (65). Recent evidence has pointed out that 
apelin/APJ system plays a critical role in the homeostatic balances of numerous 
processes (58, 64, 72). Overall, increasing evidence points out the central role of 
apelin/APJ in cell function; placing it as a potential therapeutic target for the 






Figure 6. Apelin processing.  Amino acid sequence of different apelin 
peptides isoforms.  A. (pyr1) apelin-13, B. apelin-13, C. apelin-17 and D. apelin-









Figure 7. Cardioprotective effects mediated by apelin/APJ. Apelin and APJ 
signaling contribute to normal cell function in blood vessel and adipose tissue. 




As mentioned earlier, VSMCs differentiation, proliferation and migration are key 
during the repairing process of atherosclerotic plaques. At the molecular level, 
the coordinated activity of members of the solute carrier family 12A (SLC12A) is 
central to controlling cell volume and thereby cell proliferation and migration. 
Therefore in the following paragraphs the role and activity of SLC12A members 
will be discussed.  
 
SLC12A-Cation Chloride Cotransporters 
Members of the SLC12A are among the most important mechanisms to 
coordinate osmotic water influx and efflux. Based on homology and sequence 
identity, the SLC12A family is composed of at least eight cation chloride 
cotransporters (CCCs) members: three Na+-dependent inwardly oriented (NCC, 
NKCC1 and NKCC2), four outwardly oriented K+-dependent and Na+-
independent (KCC1 to 4), a cation chloride cotransporter interacting protein (CIP) 
and probably the polyamine transporter (CCC9) (75, 76) (Figure 8). Tight control 
of cell volume is of paramount importance to sustain normal cell function and 





Figure 8. SLC12A family of cation chloride cotransporters. Schematic 
representation of SLC12A members of cation-chloride cotransporter. The 
potassium-driven chloride cotransporter (KCC1-4) mediate the efflux of 
chloride. NKCCs and KCCs participate actively in RVD and RVI by promoting 





When cell volume is perturbed, volume restoration mechanisms are activated in 
order to maintain cellular homeostasis. These mechanisms involve the 
coordinated function of CCC, channels, exchangers and sodium potassium 
ATPase (i.e. Na+/K+ pump) to change the intracellular concentration of organic 
and inorganic osmolytes and ultimately the osmotic influx/efflux of water.  
 
Efflux of potassium (K+), chloride (Cl-) and organic osmolytes takes place to bring 
cell volume back to normal to counteract the exposure to hypotonic extracellular 
conditions that would lead to uncontrolled cell swelling. This volume restoration is 
achieved through stimulation of: K+ and Cl- channels, along with K+-Cl- 
cotransporters (known collectively as KCCs). Altogether they mediate the exit of 
K+ and Cl- associated with water efflux (78-80).  Similarly, when cells are exposed 
to hypertonic stimuli and as a way to prevent cell shrinkage, a series of events 
known as regulatory volume increase response (RVI) are triggered to increase 
the intracellular osmolyte concentration and water influx. RVI results in 
restoration of cell volume through activation of the sodium/potassium (Na+/K+) 
pump, sodium-potassium-two chloride (Na+-K+-2Cl-) cotransporter (NKCC), along 
with chloride/bicarbonate (Cl-/HCO3-) and sodium/proton (Na+/H+) exchanger (81, 




Figure 9. Regulatory mechanisms to keep cell volume constant. During 
hypotonic or hypertonic challenges, RVD or RVI response take place to prevent 
cell death by cell swelling or shrinkage. During RVD, KCCs’ activity is 
upregulated to facilitate water osmotic efflux whereas NKCCs’ activity is 




The Cation-Chloride Cotransporters (CCCs) and the Na+/K+ pump  
The CCCs are secondary active transporters, as there is no ATP utilization and 
therefore rely on the chemical gradient generated by the Na+/K+-ATPase to move 
Cl- against its electrochemical gradient (83-86). Structurally, they are predicted to 
have 12 transmembrane segments and long intracellular amino and carboxy 
termini. Normally, NKCCs transport ions at a ratio of 1Na+:1K+:2Cl-, NCC at a 
ratio of 1Na+:1Cl-, and KCCs at 1K+:1Cl- ratio. The stoichiometry for all CCC 
results in electroneutral movement as the net charge traversing the plasma 
membrane is zero and thus, they are classified as electroneutral cation-coupled-
anion transporters (76, 87). These cotransporters share a 47-60 % identity in 
amino acids among each other (88).  
   
In VSMCs, expression of several members of the SLC12A has been reported 
(89-91). NKCC1, KCC1, 3 and 4 actively participate in several cellular processes 
such as regulation of cell volume, differentiation, motility and proliferation (91). 
NKCC1 is a protein of 1212 amino acids, encoded by the SLC12A2 gene located 
on chromosome 5q23 (92). NKCC1 exhibits ubiquitous expression and is target 
of tissue specific posttranslational modifications (glycosylation) that result in 
proteins ranging from 135 kDa to 195 KDa (93). NKCC1 is known to function as a 
homodimer and is predicted to have a hydrophobic core of 12 TMD and long N- 
and C-terminal cytoplasmic domains. They bear a long hydrophilic extracellular 
loop (ECL) between TMD 7 and TMD 8 which is target for glycosylation (92, 94-
96). NKCC1 activity can be inhibited by loop diuretics bumetanide and 




resolved. Using chimeric protein approaches and point mutation strategies, it is 
believed that they are localized across the hydrophobic core of the TM domain. 
Cation binding is primarily localized on TM2 domain, Cl- binding involves TM4 
and TM7 domains, and bumetanide binding includes multiple domains 
comprising TM2, TM7, TM11 and TM12. The N- and C- termini do not participate 
in ion binding (97-99).  
 
NKCC1 activity is tightly linked to its phosphorylation state. Phosphorylation of 
three N- terminal threonine residues (Thr-184, 189 and 202) and Thr-1114 on the 
C-terminal regions have been identified as modulators of NKCC1 trafficking and 
activity (93-95, 100).  
 
These sites are phosphorylated via two serine threonine kinases: the Ste-related 
proline-alanine-rich kinase (SPAK) and the oxidative stress response 1 kinase 
(OSR1). Protein phosphatase 1 (PP1) removes these phosphates and 
inactivates the cotransporter. These protein kinases and phosphatases physically 
interact with NKCC1 through overlapping binding motifs within NKCC1 N-terminal 
region, highlighting a coordinate modulation of the NKCC1 activity (Figure 10) 
(101).   
 
Besides NKCC1, VSMCs highly express several KCCs (KCC1, 3-4) and very low 
levels of KCC2, which actively participate in modulating cellular volume and ionic 
homeostasis (102-105). Apelin relevance in regulating the three signaling 
pathways described in the preceding sections lies in the fact that the newly 




detail by Drs. Peter Lauf and Norma Adragna from our laboratory in the US and 
by Drs. Clive Ellory and Philip Dunham in the United Kingdom (90).  
 
The KCC share roughly 30 % identity in amino acids with other CCCs family 
members.  Their primary structure is predicted to be of 12 trans-membrane (TM) 
domains with both N and C termini located in the cytoplasm and a glycosylated 
extracellular loop between TM 5 and TM 6 (76, 88, 106-108). The 12 TM 
segments are highly-conserved regions, and the C-terminus domain is even 
more conserved compared to the N-terminus domain. The cation binding sites in 
TMD2 have been established through chimera work, whereas, the anion binding 
sites are less defined, involving several domains of the molecule (88, 97). Both N 
and C-termini domains have consensus phosphorylation sites for kinases and 
phosphatases and are involved in signal transduction (Figure 10) (76).  The 
transporter is highly selective for K+ and Cl- ions, possesses asymmetric kinetics 
in ion binding, mediates the electroneutral transport of ions and is important in 
cell volume regulation (109, 110).  
 
The modulation of KCC activity involves dephosphorylation of serine/threonine 
residues located within the amino and carboxy termini. Thus, the coordinated 
activity of kinases and phosphatases is important to sustain normal KCC function 
(111). Protein phosphatase 1A and 2B along with members of the “with no lysine” 
(WNKs) and STE20 (SPAK) serine kinase family are important modulators of the 
activity of KCCs and NKCCs (112-115). These proteins and kinases reciprocally 




and KCC by these kinases and their involvement in controlling in cell volume is 






















Figure 10. Coordinated regulation of K-Cl cotransporters (KCCs) and Na-
K-2Cl cotransporters (NKCCs). Phosphorylation/dephosphorylation events 
control the activity of NKCCs and KCCs during changes in osmolarity. 
PP1A/PP2 mediated dephosphorylation inhibits NKCC and activates KCC. 
The serine threonine kinases WNK and SPAK phosphorylate NKCCs and 





KCC is a ouabain- and bumetanide-insensitive transporter that mediates coupled 
K+ and Cl- bidirectional transport across the membrane (107-110).  Although the 
transporter functions bi-directionally, under physiological conditions, KCC is 
mainly directed outward (118).   
 
An important feature of KCC is its ability to be stimulated by cell swelling or by 
treatment with N-ethylmaleimide (NEM) (84, 119, 120). KCC activation by 
hypotonicity was initially observed in red blood cells and then later discovered in 
different cells of various species (120). In various cell systems, NEM selectively 
activates KCC (121, 122, 122-124). Both NEM and hypotonicity-stimulated cell 
swelling have been used as diagnostic criteria to identify the functional presence 
of KCC.  
 
To date, four KCC isoforms have been identified: KCC1, KCC2, KCC3 and KCC4 
with their distinct tissue specific expression. KCC1 and KCC3 share 75 % identity 
in their amino acids; whereas, KCC2 and KCC4 share 72 % identity in their 
amino acid residues (125, 126). Additionally, these isoforms are also capable of 
interacting with each other or one another resulting in the formation of homo-
oligomers or hetero-oligomers, respectively, most likely involving the last C-
terminal residues (127-129). 
 
KCC1 is encoded by the SLC12A4 gene located on chromosome 16q22 (88). 
The expression of KCC1 is ubiquitous (housekeeping isoform) and plays a role in 
cell volume regulation acting in reverse direction of NKCC1. While NKCC1 plays 




by enabling K+ and Cl- to exit the cell (88, 130, 131). The predicted structure of 
KCC is similar to NKCC except that the extracellular hydrophilic loop containing 
glycosylation sites are linked to TMD5 and TMD6.  
 
The KCC2 transporter was originally cloned from a mouse brain cDNA library 
(106). The protein is composed of 1116 amino acids residues and this isoform is 
encoded by the SLC12A5 gene located on chromosome 20q13. Although initial 
findings suggested localized expression in CNS due to a neuronal-restrictive 
silencing element (NRSE), recent evidence has shown its expression in 
metastatic processes and minimal mRNA expression documented in VSMCs (75, 
88, 104, 106, 125, 132, 133, 133-138). Unlike KCC1, KCC2 activity is not 
sensitive to cell volume and thus, is not stimulated upon cell volume. KCC2 
function in conjunction with NKCC1 and KCC3 to maintain neuronal excitability 
by regulating intracellular Cl- concentration. Due to differential expression of 
NKCC1 and KCC2 during the development of the central nervous system; in 
embryonic immature neurons, intracellular [Cl-] is high due to increase in activity 
of NKCC1. As the neurons undergo maturation, the expression of NKCC1 
declines and is switched by KCC2 that extrudes Cl- (139). This switch allows 
operation of γ-aminobutyric acid (GABA) receptors to induce depolarization in 
developmentally immature neurons and hyperpolarization in mature adult 
neurons.  KCC2 knockdown models display epilepsy (140, 141).  
 
KCC3 consists of 1150 amino acids residues and is encoded by the SLC12A6 




brain, muscle, kidney, liver, lung and heart. KCC3 mutations have been 
associated with Anderman’s disease. KCC4 is encoded by SLC12A7 gene that is 
located on chromosome 5p15.3 and is mainly expressed in kidney, heart, smooth 
muscle cells and to a slighter extent in the brain. KCC4 has been linked to inner 
ear function (125).  
 
The broad arrays of the physiological roles of each of the KCC isoforms have 
been studied by gene disruption in mice and the resulting phenotypes observed 
were linked to various human diseases. KCC1 and KCC3 are implicated in 
hemoglobinopathies. KCC3 is implicated in hypertension, KCC2 is associated 
with epilepsy, and KCC4 is linked to hearing disorders (76, 137, 142-145). The 
functions of each of the isoforms are shown in Table 1.  
 
VSMCs have three of these four isoforms: KCC1, KCC3 (splice variants KCC3a 
and KCC3b), and KCC4 (102, 103). KCC2a but not KCC2b, which is neuron 
specific KCC2 has been documented as fairly expressed in VSMCs and lens 
epithelial cells (132, 138). It is possible that the expression of different isoforms in 






 Table 1. Summary of KCC isoform-specific distribution and function (76, 
118, 146). 
 





KCC and signaling pathways in relation to CVD 
A substantial body of evidence suggests a role of KCC in general cellular 
homeostasis, hypertension, blood pressure regulation and cell proliferation 
stressing the need to study KCC in relation to CVD and cellular homeostasis (75, 
89, 118, 134, 145, 147). 
 
Important modulators of the expression and activities of KCC involve the 
NO/cGMP/PKG pathway (75, 102-105, 148). In addition, PDGF uses PI3K/Akt-
mediated pathway in vascular smooth muscle cells (VSMCs) to regulate KCC 
(149, 150). Furthermore, KCC1 and KCC3 are regulated via the 
phosphoinositol/PKC pathway in low-K sheep red cells (151). The 
NO/cGMP/PKG pathway leads to vasodilation and activates KCC, which in turn, 
plays an important role in blood pressure regulation, as shown by a hypertensive 
phenotype in mice with deletion of the KCC3 isoform (KCC3 -/-) (89, 102, 137, 
145, 145, 145, 152).  
 
In addition to regulating KCC, the NO-mediated pathway regulates VSMC 
proliferation, migration, apoptosis, extracellular matrix protein formation, and 
relaxation (153-155). The NO-pathway is also important in preventing 
atherosclerosis lesions and is activated only if VSMCs are contractile in vitro, i.e. 
before passage 4 given that PKG expression diminishes after this passage (22, 
25). The activators of the pathway, such as sodium nitroprusside (SNP), 
NONOates (NO donors), YC-1 (NO-independent activator of sGC), 8 Br-cGMP 




KT5823 (for PKG), stimulate and inhibit KCC activity, and mRNA and protein 
expression, respectively (89, 102-105, 137, 137, 152). Additionally, our 
laboratory has shown an association between KCC and atherosclerosis using the 
synthetic VSMCs as a model system, where the MAPK and PI3K/Akt signaling 
pathways play a prominent role (149, 150).   
 
Regulation of KCC by the PI3K/Akt pathway has been documented by our 
laboratory. Platelet derived growth factor (PDGF), a serum mitogen, has a 
regulatory role in the pathogenesis of atherosclerosis. In addition, PDGF 
stimulates KCC through PI3K/Akt and protein phosphatase 1 (PP-1) and induces 
VSMC proliferation (149, 150). The stimulation of KCC was blocked by a 
selective inhibitor of the pathway, suggesting regulation of KCC by the PI3K/Akt 
pathway (75, 149, 150). Finally, regulation of KCC by MAPK, initially documented 
in sheep red blood cells and was later confirmed in successive studies on 
cervical carcinoma (134, 151, 156, 157). In these studies, KCC stimulation was 
blocked by PD98059, a MEK selective inhibitor, and furthermore, knockdown of 
KCC decreased cervical cancer proliferation and activation of the MAPK 
signaling cascade suggesting an interdependent relationship between the MAPK 
pathway and KCC (151, 158-160).  
 
KCC in cell proliferation/migration 
Several studies have suggested serum as an important modulator of ion 
channels and transporters (150, 161, 162). Serum contains mitogens and growth 




various cultured cells. Evidence from our laboratory and others has also shown 
regulation of KCC by growth factors or mitogens that is involved in cell 
proliferation. Serum factors were essential for basal KCC activity maintenance 
(150).  Serum deprivation for twenty four hours abolished KCC activity; however, 
the effect was recovered after serum addition.  PDGF (platelet derived growth 
factor), a major mitogen/growth factor for cells of mesenchymal origin present in 
serum, is also prevalent in atherosclerotic lesions. PDGF, a potent chemo-
attractant induces cell proliferation in VSMCs during atherosclerosis. In cell 
culture, PDGF utilizes a MAPK pathway to initiate cell proliferation. Our 
laboratory has demonstrated that PDGF activates KCC in a time- and dose-
dependent manner: both acutely and chronically via a PDGF receptor (149, 150). 
Primarily, PDGF increases overall protein content in cultured VSMCs 
demonstrating the effect of PDGF on cell proliferation, which is an important 
mechanism observed during atherosclerosis. Since VSMCs migration is an initial 
step in formation of atherosclerotic lesions, evidence of KCC in cell migration has 
been documented in studies involving various models.  
 
Cell migration is important in several physiological and pathophysiological 
processes including cell volume regulation, embryogenesis, tumor metastases, 
wound healing, inflammation, immune defense, atherosclerosis and tissue 
remodeling (163). Several lines of evidence have demonstrated KCC playing a 





Previous research has shown an interrelationship between cell migration and 
KCC activity studies using cancer cell lines showed. An insulin-like growth factor-
1 (IGF-1) receptor has been shown to regulate KCC production by activating 
PI3K and Erk1/2 MAPK pathways in cancerous cells (133, 157, 164). Knockdown 
of KCC significantly reduced cell migration. This indicates the importance of KCC 
to modulate IGF-1-dependent cell migration and invasion in cancer.  
 
KCCs and apelin 
Noteworthy, similar and overlapping regulatory networks converge to regulate 
apelin-mediated effects and potassium-chloride cotransport by KCCs, the latter 
being ultimately determined through phosphorylation /dephosphorylation events. 
For instance, high levels and dysregulated oxLDL uptake by the fatty acid 
translocase CD36 (atherosclerosis hallmark), result in pronounced upregulation 
of KCC1 (166).  At the molecular level, KCCs activity has been shown to be 
modulated by the NO, PI3K/Akt and MAPK/ERK1/2 signaling networks, through 
which apelin elicits its cardioprotective effects (89, 137, 145, 152).  Altogether, 
the evidence presented in this thesis suggests a strong link between apelin-
mediated cardioprotective effect and KCC activity (Figure 11). Since KCC 
activity has proven to be required for controlling cell volume, migration, 
proliferation and vascular remodeling, we endeavor in establishing a connection 






















Figure 11. SLC12A family of Cation Chloride Cotransporters. Overlapping 
signaling cascades regulate the activity of K+-Cl- cotransporters and apelin 




DEVELOPMENT OF THE HYPOTHESIS  
Apelin/APJ is an important modulator of fluid homeostasis and cell volume. Its 
stimulation displays important cardio-protective functions by reducing blood 
pressure levels and counteracting the effect of oxLDL. In atherosclerosis, VSMCs 
migration/proliferation in combination with high circulating levels of oxLDL 
accelerates atherosclerosis progression and blood vessels lesion formation. 
Since cell migration/proliferation and cell volume are tightly linked to K-Cl activity, 
and extensive overlap exists between the apelin-mediated signaling pathways 
(NO, PI3K/Akt, MAPK) and K-Cl cotransport mode of regulation: I hypothesize 
that oxLDL and apelin/APJ are important modulators of K-Cl activity to 
sustain cell volume regulation, and normal cardiovascular function. In 
addition, because K-Cl cotransport activity is dependent on several factors, 
such as, serum, ionic strength, osmolality, cell proliferation and migration, 
it is possible that the apelin-mediated effect on K-Cl cotransport could also 
be dependent on the aforementioned factors.  
 
GOAL: To obtain a better understanding of K-Cl cotransport activity in VSMCs 
and to establish whether apelin/APJ exerts an effect on K-Cl cotransport activity 




SPECIFIC AIMS  
 
Specific Aim 1: To characterize K-Cl cotransport in VSMCs and to examine a 
possible link to VSMCs phenotype. 
Since synthetic VSMCs are highly proliferative and cell 
migration/proliferation strongly relies on K-Cl cotransport and dynamic 
rearrangements of cytoskeletal proteins, it is likely that during VSMCs’ 
dedifferentiation, changes in K-Cl cotransport expression and activity, and 
expression of cytoskeletal markers take place to sustain VSMCs’ transition 
to synthetic states. 
 
Specific Aim 2: To determine the acute and chronic effect of apelin on K-Cl 
cotransport activity in VSMCs. To establish the involvement of NO, PI3K/Akt and 
MAPK signaling pathways in the regulation of the transporter.  
 
Specific Aim 3: To assess the factors, such as, serum, osmolality, ionic 
strength, VSMCs phenotypes on apelin-mediated effect on K-Cl cotransport 
activity. The above factors will shed light on possible variability in the apelin 






MATERIALS AND METHODS  
Chemicals. Rubidium chloride (RbCl, 99.8 % purity metal basis) and 
amidosulfonic acid (99.99 % purity, metal basis) were purchased from Alfa Aesar 
(Ward Hill, MA). Potassium chloride (KCl), sodium hydroxide (NaOH), 
magnesium chloride (MgCl2), 2-[4-(2-hydroxyethyl)piperazin-1-yl] ethanesulfonic 
acid (HEPES), Tris, D-glucose, sucrose, calcium chloride (CaCl2), calcium 
gluconate, N-methyl D-Glucamine (NMDG), Minimum Essential Medium (MEM) 
Alpha Medium, low glucose Dulbecco’s Modified Eagle’s culture medium 
(DMEM), fetal bovine serum (FBS), 0.25 % trypsin, Western blot gel loading 
buffer (10X), molecular weight protein ladder, and 70 % perchloric acid (PCA) 
were procured from Thermo Fisher Scientific (Waltham, MA). Penicillin (10,000 
units/mL), streptomycin (10,000 µg/mL) and cesium chloride (CsCl) were 
acquired from Life Technologies (Carlsbad, CA). Magnesium gluconate, 3-[N-
morpholino] propane sulfonic acid (MOPS), and bovine serum albumin (BSA) 
were purchased from Sigma-Aldrich (St. Louis, MO).  
 
Bicinchonic acid (BCA) protein kit, mammalian protein extraction reagent (M-
Per), radioimmunoprecipitation assay (RIPA) buffer, Halt protease inhibitor and 
enhanced chemiluminescence (ECL) substrate were from Pierce (Rockford, IL). 




Bumetanide was acquired from MP Biomedicals (Solon, OH). Apelin-13 (catalog 
# 60833) was acquired from Anaspec (Fremont, CA). Inhibitors of the PKG, 
PI3K/Akt and MAPK signaling pathways (KT5823 (catalog # 420321), LY294002 
(catalog # 19-142) and PD98059 (catalog # 513000), respectively) were 
purchased from Calbiochem (Billerica, MA). oxLDL (catalog # STA-214) was 
purchased from Cell BioLabs (San Diego, CA). Collagenase type II (catalog # 
171049-019) was purchased from GIBCO BRL (San Francisco, CA). 
 
Antibodies.  Polyclonal rabbit anti-PKG antibody was purchased from BioVision 
(San Francisco, CA). Mouse (ms) anti-α-actin and rabbit (rb) monoclonal anti-
vimentin were from Cell Signaling (Danvers, MA). ms anti-β-actin was acquired 
from Santa Cruz (Dallas, TX), and ms anti-desmin was procured from BD 
Pharmigen Co (San Jose, CA). Rabbit polyclonal anti-apelin receptor (APJ) was 
purchased from EMD Millipore (Billerica, MA). Rabbit polyclonal KCC4 antibody 
was purchased from Chemicon International. KCC1 non-commercial antibody 
was generated by traditional rabbit immunization procedures developed by 
Gagnon and Lauf (167). Epitope used to raise KCC1 antibody corresponded to 
sequences within third extracellular loop (ECL3) (167).  
 
Extraction of primary cultures of VSMCs.  Enzymatic dispersion of rat aortic 
VSMCs was performed as previously described (150). Aortas from Sprague 
Dawley rats (150-200 g) were washed three times in Minimum Essential Medium 
(MEM) alpha medium. Then, aortas were mechanically stripped of fat and 




mechanically removing the tunica adventitia, tissue was cut into smaller 
segments and incubated at 37 °C with a trypsin and collagenase II solution until a 
single cell suspension was obtained (Figure 12). Cells were centrifuged and 
resuspended in DMEM medium containing 10 % fetal bovine serum (FBS), and 
diluted to obtain a final concentration of 4 x 105 cells/mL. Finally, cells were 
plated into 75 cm2 tissue culture flasks (T-75) and grown in DMEM containing 10 
% FBS and supplemented with penicillin (50 units/mL) and streptomycin (50 
µg/mL) at controlled atmosphere of 95% O2/ 5% CO2 at 37 oC. Growth media 
was replaced every two days until cells were 100 % confluent. Standard 
trypsinization was performed to split cells (1:4 ratio) into new T-75 flasks or 12-
well plates, depending upon the experimental requirements. Cells at passages 1-
4 were considered as contractile VSMCs, whereas passages 6-75 were used as 
synthetic VSMCs based on previous phenotype characterization reports as 




Figure 12. VSMCs isolation from Sprague Dawley’s thoracic aorta. 
Single VSMCs were isolated by incubating aorta with a collagenase and 




Solutions used for Rubidium (Rb+) transport studies.  
Several buffers were used during the transport studies to determine K-Cl 
cotransport activity. Examination of Rb+ transport under isotonicity was 
performed by incubating VSMCs in a balanced salt solution (BSS-NaCl) 
composed of 20 mM HEPES-Tris buffer (pH 7.4 at 37 oC) containing (in mM): 
NaCl (130), KCl (5), CaCl2 (2), MgCl2 (1), glucose (10). The preincubation 
solution contained 0.1 % BSA in BSS. The flux solution replaced 5 mM K+ with 
10 mM Rb+.  
 
The Cl--free media contained sulfamate (Sf-) in the K+, Rb+, and Na+ salts, and 
gluconate in Mg+2 and Ca+2 salts. Na+-free media contained: NMDG in Cl- or Sf- 
salts. A wash buffer to terminate Rb+ uptake was composed of 10 mM MOPS-
Tris, MgCl2 of pH 7.4 (300 mOsM). Osmolality was changed by varying the ionic 
strength of the solution with variable amounts of NaCl, NaSf, NMDGCl or 
NMDGSf salts while keeping the other ions constant. In some experiments, 
osmolality was increased by using sucrose maintaining the constant ionic 
strength.  Osmolality (in mOsm/kg H2O) of the hypotonic, isotonic and hypertonic 
solutions were 120, 300 and 450, respectively. Ouabain (2 mM) and bumetanide 
(2-30 µM) was used to fully inhibit Rb+/K+ fluxes by the Na+/K+ pump and the 
sodium-potassium-two chloride cotransporter (Na+-K+-2Cl-) activities, respectively 
(Figure 13).  
 
All stock salt solutions were prepared in deionized water. Stock solutions of the 




LY294002, PD98059 were prepared in DMSO as solvent. The osmolalities 
(osmol/kg H2O) of the salt solutions were measured with Advanced Micro-





Figure 13. Schematic representation of various K+ transport mechanisms 
in VSMCs. Potassium chloride cotransport (KCCs) can be inhibited by 
furosemide or chloride (Cl-)-free media. In our experimental design, the anion 
sulfamate (Sf-) was used to study the “leak” pathway represented by other K+ 
channels that might be present in VSMCs. K-Cl Cotransport corresponds to the 
differences in Rb+ influx in Cl- and sulfamate (Sf-) media in the presence of 





Rb+ transport studies. K-Cl cotransport activity was measured using previously 
established protocols in VSMCs with slight modifications (150, 152). Confluent 
monolayers of VSMCs grown into 12 well plates were rinsed three times with 
BSS and then equilibrated for 10 min in preincubation media. Several flux 
timeframes (from 0-40 min) were used to determine K-Cl cotransport activity, 
which was normalized to protein concentration. Addition of ouabain and 
bumetanide during preincubation and flux periods prevented  K+/Rb+ movement 
mediated by Na+/K+ pump and Na+-K+-2Cl- cotransporters, respectively. Rb+ flux 
was terminated by washing cells with ice cold 10 mM MOPS-Tris, MgCl2. 
Intracellular Rb+ was released from cells by incubating them in 5 % PCA-4 mM 
CsCl 15 min at 4 oC and measured by using a Perkin-Elmer 5000 Atomic 
Absorption Spectrophotometer (AAS) in the emission mode (148, 150). Next, 
cells were solubilized with 1N NaOH for 30 min at room temperature and protein 
concentration was determined using BCA protein assay. Quantification of protein 
was performed using Labsystems Multiskan MCC/340 plate reader following 
manufacturer’s guidelines (Figure 14). The difference between Rb+ transport in 
the presence of Cl- and Sf- was used to determine Cl--dependent Rb+ influx (i.e. 
K-Cl cotransport activity).  
 
Apelin studies. Previously described Rb+ flux studies were performed with minor 
changes: When required, VSMCs were serum deprived for 24 h at sub-
confluence prior to an experiment. Apelin (1 µM) was added either during flux 





Solutions for Rb+ transport studies (e.g., Na+ containing solution) 
Initial wash solutions 
Balanced salt solution (BSS-NaCl):  20 mM Hepes-Tris, 5 mM KCl, 2 mM 
CaCl2, 1 mM MgCl2, 10 mM glucose and NaCl, pH 7.4, 37 oC, 300 mOsM. 
 
BSS-NaSf: 20 mM Hepes-Tris, 5 mM KSf, 2 mM calcium gluconate, 1 mM 
magnesium gluconate, 10 mM glucose and NaSf, pH 7.4, 37 oC, 300 mOsM. 
Preincubation solutions 
BSS-NaCl-BSA: 20 mM Hepes-Tris, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 
mM glucose, 0.1% BSA and NaCl, pH 7.4, 37 oC, 300 mOsM. 
 
BSS-NaSf-BSA: 20 mM Hepes-Tris, 5 mM KSf, 2 mM calcium gluconate, 1 mM 
magnesium gluconate, 10 mM glucose, 0.1% BSA and NaSf, pH 7.4, 37 oC, 300 
mOsM. 
Flux solutions 
BSS-RbCl-NaCl-BSA:  20 mM Hepes-Tris,10 mM RbCl, 2 mM CaCl2, 1 mM 
MgCl2, 10 mM glucose, 0.1% BSA and NaCl, pH 7.4, 37 oC, 300 mOsM. 
 
BSS-RbS-NaSf-BSA: 20 mM Hepes-Tris, 10 mM RbSf, 2 mM calcium gluconate, 
1 mM magnesium gluconate, 10 mM glucose, 0.1% BSA and NaSf, pH 7.4, 37 
oC, 300 mOsM. 
Final wash solution 
10 mM MOPS-Tris, MgCl2, pH 7.4, 4 oC, 300 mOsM. 
Rb+ extraction 
5% perchloric acid (PCA), 4 mM CsCl 





Figure 14. Summary of steps for assessing Rb+ influx in VSMCs.  Washed 
VSMCs were loaded with Rb+ (5-40 min), then Rb+ ion was extracted by PCA 
and ion concentration was measured by AAS. Protein was solubilized by 1 N 




Protein extraction. Total extracts from VSMCs were obtained using either M-
PER and/or RIPA lysis and extraction buffers (Pierce Biotechnology). In all cases 
manufacturer’s guidelines were followed accordingly. VSMCs were grown into 
100 mm petri dish. Confluent monolayers were rinsed with cold PBS and 
resuspended in lysis buffer at 4 oC in the presence of protein-phosphatase and 
protease inhibitors. Total cellular protein extracts were obtained using a cell 
scrapper, then sonicating 5 pulses for 5 seconds followed by centrifugation at 
14,000 g for 10 min. The protein concentration of the supernatant was 
determined according to the BCA protein assay. Protein samples were stored at - 
20 oC until used for Western blot analysis.   
 
Western blot (WB) analysis. Standard Western blot procedures were performed 
as described elsewhere with slight modifications (148, 149). Equal amount of 
proteins of contractile and/or synthetic VSMCs were resolved by 7.5 and/or 8.5 % 
SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes 
using a semidry system. Membranes were blocked with 10 % nonfat dry milk 
and/or 5 % BSA in Tris-buffered saline and 0.05 % tween 20 (TBS-T) for 1h at 
room temperature (RT). Membranes were then exposed overnight at 4 oC to 
primary antibodies against: mouse (ms) anti-α-actin (1:1000), rabbit (rb) anti-
vimentin (1:1000), ms anti-desmin (1:1000), rb anti-KCC1 (1:250), rb anti-KCC4 
(1:500), and polyclonal rb anti-APJ (1:1000). Similar protein loading was verified 
by probing membranes with ms anti-β-actin (1:1000). PVDF membranes were 
then washed extensively in TBS-T and incubated for 2 h with the appropriate 




(1:3000) and/or donkey anti-ms (1:3000) in 10 % nonfat dry milk in TBS-T. Prior 
to detection, membranes were washed three times in TBS-T and enhanced 
chemiluminescence (ECL) was used for visualization of immunocomplexes using 
a high resolution Fuji LAS3000 CCD camera. Band densitometry was performed 
by computer software attached to a Kodak camera and/or ImageJ software to 
determine the changes in protein expression.  
  
Immunofluorescence. The immunofluorescence procedure was described 
elsewhere (137, 138). Here with slight protocol modifications, protein localization 
patterns for α-actin, PKG and APJ receptor were determined from contractile 
and/or synthetic VSMCs at 25 % confluency. VSMCs were seeded in 8-well 
chamber slides (Lab-Tech; NUNC) at a density of 8 x 104 cells/well, washed with 
ice cold 1X PBS, fixed with 0.5 mL/well of 4 % paraformaldehyde (± saponin) for 
30 min at 4 oC, then incubated in 0.5 mL/well 3 % of normal goat/donkey serum 
(NGS/NDS) for 1h at 4 oC to block non-specific immune staining. After serum 
removal, cells were incubated with corresponding primary antibodies at the 
following concentrations: ms monoclonal anti-α-actin (1:250) in 3 % NGS, rb 
polyclonal anti-APJ (1:100) in 3 % NDS and rb anti-PKG (1:100) in 3 % NDS 
overnight at 4 oC. Samples incubated with only primary or secondary antibodies 
were used to assess specificity of the antibodies used. Cells were then washed 
twice with ice cold PBS followed by incubation with anti-ms IgG-FITC (1:1000), or 
anti-rb FITC (1:100), or donkey anti-rb Cy3 (1:200) for 1 to 2 h at room 
temperature (RT). Finally, cells were washed in cold PBS and with deionized 




DAPI) to visualize cell nuclei. Slides were imaged with an inverted Nikon E400 
fluorescent microscope using 100X to 400X (oil) magnification and then 
superimposed using GIMP software.  
 
Statistical analysis. Graphs were generated using Origin 7.0 (Origin Labs, 
Northampton MA) and STATISTIX 7 software (Analytical software, Tallahassee 
FL). Most results shown are product of at least two independent experiments with 
multiple determinations per condition. Data are reported as mean ± SD or SEM. 
Unpaired t-test or One-way ANOVA was performed using Graph pad Prism 5 





RESULTS: Specific Aim 1 
Growth rate of VSMCs with passage number and according to the 
phenotype (contractile and synthetic). 
This study utilizes cultured VSMCs as a model system to provide insight into a 
better understanding of the differences between VSMCs phenotypes (28). 
Several reports correlate VSMCs passage number with their respective 
phenotypes. VSMCs at passages 0-4 have been defined as predominantly 
contractile, at passage 5 intermediate, and at passages 6 and later as synthetic 
(25, 168, 169). Thus, an important factor in characterizing VSMCs properties is 
the time for them to proliferate in culture. When seeded at a constant density, an 
inverse correlation between time to reach confluence and VSMCs passage 
number was observed. For the purpose of comparison, the synthetic VSMCs 
populations were grouped based on their passage number: early (6-15); medium 
(30-45); and late (70-80). Contractile VSMCs (passages 0-4) required 10-14 days 
to reach confluence, whereas, early synthetic phenotype cells achieved 
maximum confluence in 4-6 days, and medium and late synthetic phenotype cells 




VSMC phenotypic determination by specific markers 
The phenotypic transition of VSMCs from contractile to synthetic can be studied 
using specific protein markers (e.g., α-actin, myosin, desmin, vimentin, 
osteopontin, and others) that are either up- or down-regulated depending upon 
the differentiation state of the cells (17-19). Thus, the phenotypic identity of the in 
vitro cell populations with antibodies against specific contractile protein markers 
was confirmed using SDS-PAGE and Western blotting. 
 
In late synthetic VSMCs phenotype (passage ≥ 70), there was a 60 % reduction 
in α-actin (Figure 16A), a 25 % reduction in vimentin (Figure 16B), and a 90 % 
reduction in desmin protein expression (Figure 16C). Consistent with the 
decrease in α-actin seen in Figure 16, immunofluorescence labeling of α-actin 
expression in early and late synthetic VSMCs showed an abundance of 
filamentous α-actin in the cytoplasmic compartment of early passage VSMCs 
(Figure 17A), whereas in higher passages, α-actin was redistributed or 






Figure 15. Time to reach confluency of vascular smooth muscle cell 
(VSMC) cultures as a function of passage number. VSMCs at various 
passages (0 – 90) were seeded in T-75 flasks at constant seeding density of 5 x 
105 cells/mL per flask. Y-axis shows time (days) to reach confluence in culture 
and in the X-axis the passage number. VSMCs at earlier passages (passage 0-4) 
were predominantly contractile whereas those at higher passages (≥ 6) 








Figure 16.  Characterization of VSMCs phenotypes in culture with respect 
to specific protein markers. Western blots of a representative experiment for 
low (L, passage 6), medium (M, passage 38) and high (H, passage 74) passage 
VSMCs. Panel A. ~ 43 kDa α-actin.  Panel B. ~ 57 kDa vimentin.  Panel C. ~ 53 
kDa Desmin.  Densitometric quantitation of the protein bands shown in A-C were 
normalized to β-actin (internal control), and then the quantified protein bands of 
M and H passages were normalized to basal expression levels (L as a baseline 

















Figure 17. Immunolocalization and distribution of α-actin contractile protein 
marker in early and late passage synthetic VSMCs. Immunofluorescence of 
FITC-labeled α-actin and DAPI-labeled nuclei in early (Panel A,  passage 6) and 







K+ influx pathways in VSMCs  
Non-radioactive rubidium (85Rb+) has been used as a potassium congener in 
previous ion flux studies (110, 110, 150, 170, 171). In order to isolate the portion 
of Rb+ influx that moves through KCC, three Rb+ uptake components were 
measured: (1) the total Rb+ uptake in the absence of inhibitors (T), (2) in the 
presence of ouabain (oua), and (3) in the presence of ouabain and bumetanide 
(oua + bum) as described elsewhere (171). Rb+ uptake through the ouabain-
sensitive Na+/K+ pump, the ouabain-insensitive and bumetanide-sensitive NKCC, 
and [ouabain + bumetanide]-insensitive K+ "leak" component containing the KCC 
and K+ channels, were calculated as a function of time. Initial rates for Na+/K+ 
pump and NKCC were linear up to 5 min. The remaining ouabain- and 
bumetanide-insensitive portions of Rb+ influx were linear up to 15 min (Figure 
18). In addition, percent Rb+ uptake-mediated by NKCC was higher than 
transport via the Na+/K+ pump. Higher transport velocity of NKCC suggests that 
in VSMCs, there are more copies of NKCC with higher turnover rate, or they are 
mostly activated by phosphorylation. For both the pump and NKCC, the 
equilibration was achieved by 20 min (Figure 19).  
 
To study in greater detail KCC in VSMCs, the concentration of ouabain and 
bumetanide to block the Na+/K+ pump and NKCC were optimized. First, we 
determined the ouabain concentration at which complete inhibition of Rb+ 
transport via the Na+/K+ pump occurs in VSMCs (Figure 20). In order to achieve 
that, Rb+ influx was measured from confluent VSMCs incubated with ouabain 




the experiment (preincubation and flux; 15 min), or only during flux time period (5 
min). Data revealed a 45 % and 65 % reduction in total Rb+ transport when 
ouabain concentrations (≥ 2 mM) were present during flux or throughout the 
whole course of the experiment. Notably, higher ouabain concentrations were 
required to inhibit Na+/K+ pump activity compared to previous reports using 
different cell types (eg. Human lens epithelial cells (HLEC), human embroyonic 
kidney (HEK-293) cells, etc.) (171, 172). Since the alpha subunit of the Na+/K+ 
pump is targeted by ouabain, and differences in ouabain sensitivity have been 
reported among isoforms (1<2<3); it is possible that alpha 1 isoforms with 
low ouabain affinity are highly and predominantly expressed in VSMCs (173, 
174).  
 
After determining the optimal ouabain concentration to inhibit the Rb+ mediated 
flux via  the Na+/K+ pump, similar studies including bumetanide at concentrations 
up to 20 M were carried out to further dissect the KCC-mediated Rb+ transport 
fraction. As seen in Figure 21, 80 % inhibition of Rb+ transport was obtained 
when bumetanide (>1 M) and ouabain (2 mM) were present during 
preincubation and flux time periods. In VSMCs, the IC50 for bumetanide was 0.1 
M. Interestingly, bumetanide concentrations in the nanomolar range displayed a 
stimulatory effect on Rb+ influx. To date, the mechanisms behind this initial and 









Figure 18. Characterization of Rb+ uptake in VSMCs via various K+ 
transport pathways. Rb+ uptake (nmoles/mg protein) as a function of time (min) 
was tested under isotonic (300 mOsM) conditions. Total Rb+ uptake was 
measured in the absence of inhibitors (Total, squares), in the presence of 
ouabain (1mM) (Oua, circle), and in the presence of ouabain (1 mM) and 
bumetanide (10 µM) (Oua + Bum, triangle).  Na+/K+ pump is the difference 
between Rb+ uptake in the absence of inhibitors (Total) and in the presence of 
ouabain (Oua). NKCC is the difference between Rb+ transport in the presence of 
ouabain (Oua), and ouabain + bumetanide (Oua + Bum). Finally, KCC and “leak” 
mediated by K+ channels is Rb+ transport in the presence of ouabain and 
bumetanide (Oua + Bum). Data shown is a representation of three independent 





Figure 19. Percent Rb+ uptake-mediated via NKCC and Na+/K+ pump in 
VSMCs. Rb+ uptakes-mediated by NKCC and Na+/K+ pump were normalized to 
that of total uptake in the absence of any inhibitors. NKCC and Na+/K+ pump-
mediated uptakes were calculated as described in Material and Methods and 
previous section. Normalized Rb+ uptake increased parabolic with time for NKCC 
and Na+/K+ pump and equilibrated at 20 min. Data shown is a representative 
experiment done in triplicates. For each condition, data reported is mean ± SD (n 






Figure 20. Determination of ouabain concentration optimally inhibiting the 
Na+/K+ pump in VSMCs. VSMCs were grown up to confluence and washed 
three times with BSS as described in Materials and Methods. The ouabain-
sensitive flux (OSF) was calculated as the difference between Rb+ influx in the 
presence and absence of ouabain and is plotted here as function of ouabain in 
flux only (filled squares) or with combination in preincubation and flux (filled 
circles). Data fitted with Boltzmann function revealed that ouabain concentrations 
≥ 2 mM, when present during flux periods resulted in a 45 % of reduction in Rb+ 
transport (filled squares). Further inhibition of Rb+ transport (up to 65 %) was 
attained when ouabain was present during preincubation and flux periods (filled 
circles). Data shown are mean ± SD of a representative experiment done in 





Figure 21. Bumetanide dose-response curves in rat aortic VSMCs.  Rb+ 
influx was determined in the presence of ouabain (2 mM) and bumetanide (0-20 
µM). With increasing bumetanide concentrations and in the presence of 2 mM 
ouabain, NKCC- and Na+/K+ pump- mediated transport mechanisms are 
removed and KCC activity can be further dissected.  Bumetanide concentrations 
above 1 M in combination with 2 mM ouabain resulted in 80 % inhibition of Rb+ 
influx. The IC50 for bumetanide was found at 0.1 M. Rb+ influx linear between 1 
and 20 M bumetanide is the to bumetanide-insensitive (BIS) "leak" pathway 
attributed to KCC + K+ channels. Data represents mean ± SD. For each 





Functional characterization of K-Cl cotransport in VSMCs  
KCC anion preference (Cl- >Br- >SCN- >I >NO3- >MeSO4-) was previously 
established by Lauf and Theg 1980, and Ellory et al 1982 in erythrocytes (84, 
121, 175) and later in VSMCs (150).  Consistent with previous findings from our 
laboratory in VSMCs (149, 150), Figure 22 shows KCC activity, calculated as the 
difference of Rb+ uptake in Cl- and Sf-, maintained  linearity up to 30 min. To 
determine an optimal extracellular [Rb+]o, that would saturate KCC, the activity of 
KCC was measured with respect to [Rb+]o and the findings are shown in Figure 
23. KCC saturation was achieved at a concentration of 20 mM [Rb+]o. Therefore 
in subsequent experiment, [Rb+]o lower than 20 mM within Km value range (10 
mM Rb+) were used to assess KCC activity.  
 
Additionally, KCC activity was tested using known stimulators of the system 
(hypotonicity and NEM) as shown in Figure 24.  Similar findings have been 
previously reported (75, 89, 90, 151, 152) and the effect was reproduced under 
the present conditions. KCC activity under hypotonic stimulus was increased by 
80 % (with respect to isotonic). The NEM concentration of 0.05 mM has been 
used to see the stimulatory effect (90).  Our studies showed NEM (0.05 mM) 
increased KCC activity by 2-fold. This mode of activation has been a hallmark of 
KCC regulation, which suggested that Rb+ influx was indeed mediated by thiol 








Figure 22. Rb+ uptake as a function of time was measured under isotonic 
condition in Cl- and Sf- media. Rb+ uptake as a function of time was measured 
in the presence of Cl- and Sf-, respectively. Ouabain (2 mM) and bumetanide (2 
µM) were present during the preincubation and flux. Rb+ uptake via KCC was 
calculated as the difference in Rb+ uptake in Cl- and Sf-, and was linear up to 30 















Figure 23. KCC as a function of varying [Rb+]o.  Rb+ uptake was measured in 
the presence of increasing concentrations of RbCl between 0 and 40 mM (Panel 
A) or RbSf (Panel B) at various time points. The slope “m” of the straight lines 
represents the Rb+ influx in Cl- and Sf-. The difference between the slopes 
represents the Cl--dependent Rb+ influx (KCC) (Panel C). VSMCs at passage 37 
were used for this study. For each time point, n = 4 and the data represent mean 






Figure 24.  Activation of KCC by hypotonicity and NEM. Percent (%) Cl--
dependent Rb+ influx (KCC) was calculated at 5 min in isotonic (control, 300 
mOSM), hypotonic (120 mOSM) and in the presence of the thiol-modifying agent 
N-ethylmaleimide, NEM (isotonic, 300 mOSM). NEM (final concentration 0.05 
mM) was present in the preincubation media as described in Material and 
Methods. NaCl was used to increase the osmolality to 300 mOsM. Ouabain (2 
mM) and bumetanide (2 µM) were present in both preincubation and flux 
solutions to inhibit Na+/K+ pump and NKCC, respectively. For each condition, n = 




KCC kinetic parameters in low and high passage synthetic VSMCs 
To determine a potential relationship between K-Cl cotransport activity and 
VSMCs’ phenotypic transition, we compared the Cl--dependent Rb+ flux in low 
and high passage synthetic cells.  In order to characterize KCC activity in early 
and late passage VSMCs,  Rb+ influx was measured as a function of [Rb+]o at 
fixed Cl- concentration ([Cl-]o ~ 145 mM) (Figure 25) or as a function of varying 
[Cl-]o at fixed [Rb+]o (10 mM) (Figure 26). Both curves show that transport of Rb+ 
across the cell membrane required presence of both external Cl- and Rb+. At 
maximal concentration of these ions, saturation was achieved as described by 
the Michaelis-Menten equation. The transport velocity reached a plateau at a 
certain substrate concentration and above which there was no substantial 
increase in uptake velocity (Figure 25A and Figure 26 A-B). The apparent 
binding affinity for Rb+ was higher than that of Cl- (Figure 25B vs Figure 26B). 
The maximal rate of Rb+ uptake was similar for both conditions (Figures 25B 
and Figure 26B). The Hill coefficient “n” for both ions was close to unity (~ 1) 
suggesting there is only one binding site for each ligand. Whether, the binding of 
each ligand appears to be independent of a previous or subsequent ligand 
binding to the same site, i.e. random order of binding, cannot be determined from 
these studies (107, 110).  
 
In low passage VSMCs, similar experiments demonstrated that the Cl--
dependent Rb+ transport activity through KCC in the presence of [Rb+]o (10 mM) 
or [Cl-]o (145 mM) resulted in a significant 50 % reduction in maximal velocity as 




The binding affinity (Km) for Rb+ at the external site of KCC was higher than the 
apparent binding affinity for Cl- (Figures 25-26 B vs E). The Hill coefficient “n” 
was 1 for both Rb+ and Cl- implying presence of one binding site for each ion as 
stated earlier (Figures 25-26 B vs E). Table 2 summarizes the average of 
several experiments for early and late synthetic VSMCs with respect to the ionic 
ligands. As shown in Table 2, the Vmax with respect to external Rb+ and Cl- was 
twice for late synthetic, the Km for Rb+ at external KCC binding sites were 
consistent in both groups. Apparent affinity for Cl- was higher (low Km value) in 
late synthetic VSMCs compared to earlier stages (Table 2).  
 
KCC expression during VSMCs phenotypic switching 
During VSMCs’ phenotypic switching, increased motility and proliferation rates 
are tightly linked to synthetic states of VSMCs. Additionally, precise control of cell 
volume and thus K-Cl cotransport activity is required to allow changes in cell 
volume and sustain cell proliferation and motility. With that in mind, we wondered 
if changes in KCC protein expression could be associated to VSMCs’ 
dedifferentiation processes. As can be seen in Figure 27 KCC1 and KCC4 total 
protein levels, assessed by Western blot, were increased in later synthetic states. 
Interestingly, upregulation of KCC4 seemed to occur earlier compared to KCC1 
(Figure 27A vs. Figure 27B). Maximal KCC1 upregulation was observed in 
VSMCs cultures at passage 74 (High) whereas KCC4 highest protein levels were 
detected at passage 38 (Med). The observed increase in KCC1 and KCC4 
expression is in accordance with higher motility and proliferation rates seen in 









Figure 25. Characterization of KCC kinetics in high passage (P 42) and low 
passage (P 8) VSMCs with respect to the external Rb+ concentration. Panels 
A-C show kinetics data for high passage and panels D-F are for low passage 
VSMCs. (A and D) Cl--dependent Rb+ influx through KCC. KCC activity was 
calculated as the difference between the Rb+ influx in Cl- and Sf-. (B and E)  
Lineweaver-Burke plot of data in (A and D) to calculate the maximal rate of Rb+ 
uptake (Vmax) by KCC, and the binding affinity (Km) for Rb+. (C and F) Hill plot 
showing the degree of co-operativity “n”. Data shown is a representative 
experiment done in quadruplicates. Data calculated is mean ± standard error      









Figure 26. Characterization of KCC kinetics in high passage (P 39) VSMCs 
and low passage (P 6) with respect to the [Cl-]o. Panels (A-C) are kinetic data 
for high passage and panels (D-F) are for low passage VSMCs. (A) KCC activity 
was calculated as the difference between the Rb+ influx in Cl- minus Sf- (“Leak”). 
KCC saturation was achieved at maximum chloride concentration (145 mM). (B) 
Lineweaver-Burke plot showing the apparent binding affinity of the external 
binding site of KCC for Cl-, and the maximal rate of Rb+ uptake (Km and Vmax, 
respectively). (C) Hill plot showing degree of co-operativity “n”. (D) KCC influx 
was decreased compared to high passage VSMCs. (E) Lineweaver-Burke plot 
showing apparent binding affinity of Cl- and maximal rate of Rb+ uptake. The Km 
was increased (low affinity) as compared to Panel B. The Vmax was decreased by 
half as compared to Panel B. (F) Hill plot showing degree of co-operativity “n” = 
1, which is similar to high passage VSMCs. The data shown is a representative 
experiment with quadruplicate measurements and the values are mean ± 











Table 2.  Summary of KCC functional properties in low and high passage 
synthetic VSMCs. The maximal velocity, Vm of Rb+ influx was calculated in the 
presence of external Rb+ and Cl- (second column). The apparent binding affinity, 
Km for Rb+ and Cl- on KCC binding site was calculated from Lineweaver Burk plot 
(third column). The Hill coefficients for both Rb+ and Cl- were close to unity ~ 1 
(fourth column).  Data shown are average of two independent experiments each 
done in quadruplicates (n=8) with respect to external Rb+ and three independent 
experiments each done in quadruplicates (n=12) with respect to external Cl- for 









Figure 27. KCC protein expression is increased in late synthetic VSMCs.  
VSMCs total extracts from cell cultures at different passage numbers (Low: 
passage 6, Med: passage 38, and High: passage 74) were obtained and 
separated by SDS-PAGE. Panel A. Normalized KCC1 expression increased in 
passage number 74. Panel B. Normalized KCC4 expression was increased in 
passage number 38. Densitometric quantitation of the protein bands were 
normalized to β-actin (internal control), and then the quantified protein bands of 
M and H passages were normalized to basal expression levels (L as a baseline 
control). Western blot shown is a representative experiment and densitometry 
quantification represents mean ± SD of two experiments for KCC1 and mean ± 






DISCUSSION: Specific Aim 1  
For long, studying VSMCs’ phenotypic switching has helped to obtain a better 
understanding of atherosclerosis progression and occurrence. Here, cultured 
VSMCs were used to investigate proliferation rates during their in vitro aging 
process. Additionally, we determined differences in cytoskeletal protein marker 
expression that facilitate VSMC phenotypic identification. Finally, K-Cl 
cotransport activity, important in cellular homeostasis and for controlling cell 
volume and migration, was characterized and optimized conditions for its study 
were established.   
 
Due to different gene expression profiles, contractile VSMCs (passages 0-4) are 
mostly non-proliferative and thus, replication rates in monolayer cultures are 
significantly longer than in synthetic populations (≥ passage 6) (Figure 15) (13, 
177). As VSMCs transition to a synthetic state, changes in expression and 
reorganization of cytoskeletal proteins are evident (30). Immunofluorescence of 
α-actin revealed dramatic changes in expression and subcellular distribution 
between contractile and late synthetic VSMCs (Figure 17).  Furthermore, 
significant decreases in protein expression levels of α-actin, desmin and vimentin 
were observed in late synthetic VSMCs compared to early states. Notably, 
desmin total expression was reduced by 90 % in late passage synthetic VSMCs 




where expression of cytoskeletal proteins and contractile machinery decreased 
during VSMCs’ transition to synthetic states. Similar results have been reported 
in blood vessel intimal thickening due to atherosclerotic lesion formation (178, 
179).  
 
Initial attempts to characterize the electroneutral K-Cl cotransport in VSMCs 
involved the finding and establishment of optimal conditions in which no other 
potassium transport mechanism was present. To achieve that, ouabain and 
bumetanide dose response curves were performed to allow identification of 
conditions at which complete ablation of Na+/K+ pump and NKCC activities could 
be obtained. Based on our results, and in accordance with previous reports 
showing that rodent Na+/K+ pump is predominantly composed of low ouabain 
affinity α1 subunits (O’Brien, WJ et al. 1994; Juhaszova, M. 1997); it is likely that 
in VSMCs, α1 subunits are predominantly expressed since higher ouabain 
concentrations (up to 2 mM) and longer incubation periods (preincubation and 
flux) were required to fully inhibit the Na+/K+ pump.  
 
Additionally, we characterized the K-Cl cotransport in VSMCs with respect to 
early and late synthetic phenotypes. K-Cl cotransport activity was assessed with 
respect to its known ligands [Rb+ and Cl-]. VSMCs of late synthetic passage had 
different transport activities and apparent affinities for Cl- as compared to early 
synthetic VSMCs (Figures 25-26, and Table 2). Rb+ transport via KCC required 
simultaneous presence of both Cl- and Rb+ ions externally. The maximal 




this increase is due to turnover changes of pre-existing KCCs or enhanced 
membrane trafficking/insertion of de novo synthesized KCC proteins, remains to 
be studied. In late synthetic VSMCs, the apparent affinity for Cl- increased, while 
the affinity for Rb+ remained fairly constant. It is possible that conformational 
changes due to KCC isoform assembly or posttranslational modifications might 
be responsible for increased Cl- affinity.  Interestingly, in both early and late 
synthetic VSMCs, KCC activity showed an obligatory coupled movement of Rb+ 
and Cl- in 1:1 stoichiometry ratio, as suggested by Hill coefficient of 1. This 
observation indicates that this mode of cotransport is electroneutral, and is in 
agreement with previously reported models (87, 180, 181). Whether, the binding 
of each ligand appears to be independent of a previous or subsequent ligand 
binding to the same site, i.e. random order of binding, cannot be determined from 
these studies (107, 110).  
 
Shedding light onto K-Cl cotransport regulation is of considerable importance 
since several lines of evidence have highlighted KCC activity in sustaining 
human health and during the occurrence of pathophysiological conditions (75, 
133, 137, 145, 158, 160, 181). Stimulation of K-Cl cotransport activity during 
hypotonicity and NEM treatment, constitute original hallmarks of this mode of 
electroneutral ionic transport. Consistent with previous findings, hypotonicity and 
NEM treatment resulted in significant stimulation of K-Cl cotransport. Therefore, it 
is likely that common signaling pathways and regulatory mechanisms are 
conserved among cell types (Figure 20) (84, 122, 180, 182-184). Previous 




upregulation is due to dephosphorylation of key serine and threonine residues 
within its C-terminus. It is likely that inhibition of kinase activities such as WNK 
and Ste20, in combination with activation of protein phosphatases like PP1/2, 
results in concomitant KCC de-phosphorylation and thus activation (185-187).  
 
Changes in KCC activities observed in Figures 25 and 26 could be explained by 
re-distribution of cytoskeletal proteins that would promote their trafficking to the 
cell membrane and recruitment of regulatory proteins (91). As cytoskeletal 
proteins regulate intracellular signaling cascades their distribution and location 
may be important for determining VSMC phenotype. Thus, any reorganization of 
the cytoskeleton or signaling molecules could affect VSMCs phenotypic 
modulation (30). Moreover, several cell culture models suggest that the 
cytoskeleton machinery is linked to cell migration (91, 188, 189). Further 
evidence also indicates emerging roles of ion channels and transporters playing 
a significant role in cell migration (163, 190, 191). During the cell migratory 
process, there is polarized distribution of ion channels or transporters due to 
structural reorganization of the cytoskeleton. Based on our findings, it is plausible 
that as VSMCs undergo phenotypic transformation; decreased interaction 
between KCC and cytoskeletal proteins could enhance membrane trafficking and 
increases in transport activity (137).  
 
We also demonstrated that during VSMCs dedifferentiation or phenotypic 
switching, KCC1 and KCC4 expression is increased. These results further 
support the notion that high levels of K-Cl cotransport activity are necessary to 




Importantly, our results suggest that up regulation of different KCC isoforms 
could be passage number-dependent. It remains to be determined whether 
changes in expression of other KCC isoforms (KCC2 and KCC3) occur during 
the studied conditions. Since KCC1 up regulation occurred at later states 
(passage 74), in which KCC4 protein levels were comparable to the ones seen at 
passage number 6; it is possible that mutually exclusive gene-expression profiles 
occur in VSMCs. In sum, at late VSMCs’ passage numbers, K-Cl cotransport 
activity is enhanced by both, and increase in enzyme kinetics (ion affinity and 
Vmax) and KCC protein levels. 
 
It is possible that the numbers of KCCs transporters do not change in the plasma 
membrane or that new KCCs are synthetized as cells undergo cell division. 
Furthermore, kinases could be involved in KCC regulation and change their 
expression pattern. In addition, it is likely that expression patterns are changing 
and those changes are responsible of the overall observation. Our data also 
showed that the transition of the VSMCs phenotype is linked to the expression 
and activity of KCC. Likewise, KCC regulation could lead to a VSMCs phenotypic 
transition with enhanced migration and proliferation. Recent studies have 
correlated the expression of KCC isoforms in embryogenesis and 
dedifferentiated cancerous cells linking KCC to tumorigenesis, cell proliferation, 
and migration (133, 134, 158-160). Similarly, VSMCs synthetic phenotypic 
transition is also linked to cell proliferation and migration (192). Thus, KCC 
activity and expression could be an important modulator of VSMCs transiting to 





The main finding of this study is that concomitant with the process of VSMCs’ 
transition from early to late synthetic phenotype, there is an increase in KCC 
functional properties. Additionally, KCC1 and KCC4 protein levels were up-
regulated, whereas considerable reductions of cytoskeletal proteins were found. 
Altogether our results suggest a link between KCC activity/expression and 







SPECIFIC AIM 2  
 
To determine the acute and chronic effect of apelin on K-Cl cotransport 
activity in VSMCs. To establish the involvement of NO, PI3K/Akt and MAPK 





RESULTS: Specific Aim 2 
Apelin receptor is expressed in VSMCs 
To establish whether the most abundant and potent form of apelin (apelin-13) 
might affect K-Cl cotransport via its membrane receptor APJ (predicted MW 
42.35 kDa), western blot analyses using total lysates from contractile and 
synthetic VSMCs were performed using the validated commercial antibody 
against APJ (Figure 28A). Since APJ protein expression has been previously 
reported and extensively studied in central nervous system, brain extracts were 
used as control for APJ immunodetection (52, 193). As shown in Figure 28A, 
differences in APJ protein expression were observed between brain samples and 
among VSMC phenotypes (contractile vs synthetic). First, there was a difference 
in size of APJ compared to predicted molecular weight between brain (~55 kDa) 
and VSMCs (~60 kDa). These differences in APJ molecular size suggest 
possible tissue-specific post-translational modifications/processing that would 
require further detailed examination. Second, in contrast to brain samples, strong 
APJ bands were detected from VSMCs samples at around 120 kDa indicating 
either nonspecific antibody binding or possible APJ oligomerization. Lastly, 
densitometric analysis of total APJ (monomeric and dimeric) normalized to b-




VSMCs’ phenotypic states. Total extracts of late synthetic VSMCs (passage 
number 41) revealed a possible reduction (30 %)  in APJ expression compared 
to contractile or early synthetic VSMCs (passage numbers 2 and 9 respectively) 
(Figure 28B). In addition, APJ immunolabeling revealed differences in its 
subcellular localization among VSMCs’ phenotypes. In synthetic VSMCs 
(passage number 17), the majority of APJ expression was homogeneously 
distributed along the cytoplasm (Figure 28C), whereas a more localized 
perinuclear immunolabelling pattern was detected in contractile states (passage 
number 2) (Figure 28D). These observed differences in protein expression 
levels, oligomerization and subcellular localization of APJ could result in 
variability of the apelin-mediated effects in different VSMCs’ phenotypes. To 
confirm primary antibody specificity, VSMCs were incubated in its absence 






Figure 28. APJ protein expression. (A) Protein extracts (40 g/lane) from brain 
and VSMCs primary cultures (synthetic and contractile) were separated by SDS-
PAGE and subsequent immuno-detection of APJ was performed. APJ monomer 
conformation was detectable around 60 kDa. Interestingly, the APJ signal from 
VSMCs was slightly different in size when compared to brain total protein extract. 
Strong immuno-detection at 120 kDa was detected in VSMCs protein extracts as 
well as weakly in brain tissue suggesting SDS resistant oligomerization. Anti-APJ 
primary antibody (1:1000) and -actin (1:2000) was used as an internal control.  
(B) Densitometric analysis of total APJ (monomeric and dimeric) relative to -
actin in VSMCs from a representative experiment. (C) Immuno-labeling of APJ in 
synthetic VSMCs. (D) Immunolabeling of APJ in contractile VSMCs. In both 
cases, VSMCs were fixed, permeabilized, and incubated with anti-APJ antibody 




(1:100). As a negative control; synthetic (C) and contractile (D) VSMCs were 
incubated with a 3% normal goat serum (NGS) and (FITC)-conjugated secondary 




Once evidence was gathered suggesting APJ protein expression in VSMCs, we 
determined the timeframe in which apelin-13 treatment would act upon the linear 
behavior on K-Cl cotransport activity. Cl--dependent Rb+ uptake from untreated 
and apelin-treated VSMCs was assessed from 0 to 40 min. K-Cl cotransport from 
1 µM apelin-treated VSMCs, was linear up to 40 min (Figure 29). Thus, 
subsequent determinations of K-Cl cotransport activity were performed within the 
aforementioned timeframe.   
 
Acute apelin regulation of K-Cl cotransport in serum-starved VSMCs 
Apelin regulation of K-Cl cotransport by the NO-mediated signaling 
pathway and the role of oxLDL 
Previous studies have shown that the guanyl cyclase PKG is one of the most 
important regulators of K-Cl cotransport and determinant of VSMCs contractile 
phenotype (22, 103, 148). In order to establish a direct link between the apelin 
effect and the NO-mediated regulation of KCC, immuno-labeling of PKG was 
performed in contractile VSMCs.  As can be seen in Figure 30A, clear immuno-
detection of PKG was observed. Primary antibody specificity was determined in 
the absence of PKG antibody (Figure 30). All slides were counterstained with 
4′,6-diamidino-2-phenylindole (DAPI) to visualize cell nuclei (Figures 28C-D and 
30B). 
To further assess whether apelin regulates K-Cl cotransport through the 
NO/cGMP/PKG pathway, VSMCs were used at < passage 4, when they are in 
the contractile state, to ensure PKG is present. VSMCs were cultured until sub 




were then incubated with 2.5 µM KT5823, a potent inhibitor of PKG for 10 min in 
preincubation media followed by additional 30 min during flux in the presence 
and absence of apelin (1 µM). The experimental outcomes of each condition 
were normalized relative to the control. As shown in Figure 31A, the inhibitor 
alone did not affect the basal K-Cl cotransport activity. Apelin treatment of serum-
starved contractile (PKG positive) VSMCs resulted in a significant increase of 
87.3 % (*p < 0.05) compared to the basal K-Cl cotransport activity. Importantly, 
when contractile VSMCs were incubated in the presence of KT5823, the apelin-
mediated increase in K-Cl cotransport was prevented suggesting that apelin uses 
NO pathway to regulate K-Cl cotransport activity.  
 
Because oxLDL modulate progression of atherosclerosis by impairing the NO-
mediated pathway in contractile VSMCs (194, 195), we tested whether oxLDL 
might affect K-Cl cotransport activity, which was shown to be modulated by 
apelin. Rb+ influx was measured in contractile VSMCs (passage 4) treated for 24 
h ± 8 μg/mL oxLDL and then followed by a 40 min incubation of 4 μM apelin.  Cl--
dependent Rb+ influx for each condition were normalized to the baseline control. 
Apelin treatment resulted in an increase in K-Cl cotransport by 2-fold (* p < 0.05); 
whereas the baseline KCC was inhibited significantly by oxLDL by over 70 % (* p 
< 0.05). The oxLDL-mediated inhibition of KCCs was restored by apelin 
treatment and importantly, similar fold of apelin-mediated activation was obtained 
from untreated VSMCs (Figure 31B). This suggests that oxLDL and apelin have 







Figure 29.  Cl--dependent Rb+ uptake as a function of time in the presence 
of apelin.  Cl--dependent Rb+ uptake was measured as a function of time from 
24 h-serum deprived VSMCs. Untreated VSMCs: (filled squares). VSMCs treated 
with 1 µM apelin for 40 min incubation time (open circles). Rb+ uptake was 
measured in the presence of ouabain (2 mM) and bumetanide (2 µM) for 10-40 








Figure 30. Immunolabeling of PKG in contractile VSMCs. Contractile VSMCs 
(passage 3) were fixed, permeabilized and incubated with anti-PKG 1 antibody. 
Cy3-conjugated secondary antibody was used against anti-PKG 1. In negative 
control VSMCs were incubated with a 3 % normal goat serum (NGS) and Cy3-











Figure 31. Apelin effect on K-Cl cotransport by the NO-mediated pathway.  
(A) KCC-mediated Rb+ uptake from 24 h-serum deprived contractile VSMCs was 
measured in the presence or absence of 1 µM apelin and 2.5 µM of KT5823, an 
inhibitor of  PKG. The experimental outcomes were normalized relative to the 
baseline control. Data represent means ± standard errors of two independent 
experiments each done in triplicates, n = 6 per conditions. *p<0.05 vs control 
group. (B) Apelin rescues oxLDL-mediated inhibition of KCC activity. KCC-
mediated Rb+ uptake, from 24h-serum deprived contractile VSMCs, was 
measured in the presence or absence of 4 μM apelin and 8 μg/mL oxLDL. 
Subconfluent cells were incubated oxLDL in serum free media for 24 h. Cells 
were then washed with BSS and Rb+ influx assay was carried out as described in 
Materials and Methods. Apelin was added during flux to see an acute effect on 
oxLDL-treated cells. Data represents mean ± standard error, n = 3 per 






Apelin regulation of K-Cl cotransport by PI3K/Akt and MAPK-mediated 
signaling pathways  
VSMCs motility and proliferation have been tightly linked to the activation of 
PI3K/Akt and MAPK signaling pathways that are important for vascular 
remodeling and repair. Similarly, apelin effects on motility involve stimulation of 
the aforementioned signaling cascades. Therefore, we assessed the effect of 
selective inhibitors of the PI3K/Akt and MAPK pathways on K-Cl cotransport 
activity in the presence or absence of apelin. Sub confluent synthetic VSMCs 
(passages 6-8) were serum starved for 24 h prior to flux measurement. Cells 
were then incubated for 10 min with 10 µM of either LY294002 or PD98059, 
selective inhibitors of PI3K/Akt and ERK1/2, respectively. Then cells were further 
incubated with these inhibitors for additional 40 min during flux in the presence or 
absence of apelin. The outcomes of each experimental condition were 
normalized to the baseline control. As can be seen in Figure 32A and 32B, 
acute apelin treatment resulted in activation of K-Cl cotransport in synthetic 
VSMCs by 142% (*p < 0.05). Baseline activity was not affected by neither of the 
inhibitors used. However, VSMCs incubated with the inhibitors were no longer 
responsive to apelin-mediated activation of K-Cl cotransport activity. These 
results point out apelin/APJ regulates KCC via PI3K/Akt and MAPK pathways. A 
summary of the signaling pathways that result in K-Cl cotransport upregulation by 
apelin and the usage of selective inhibitors are displayed in Figure 33. Inhibitors, 




the presence of apelin. OxLDL inhibitory effect on K-Cl cotransport activity was 










Figure 32. Apelin-mediated activation of KCC occurs through a PI3K/Akt 
and MAPK pathways in synthetic VSMCs. (A) Apelin-mediated activation of 
KCC occurs through the PI3K/Akt pathway. KCC-mediated Rb+ uptake by 24 h-
serum deprived synthetic VSMCs was measured, according to Materials and 
Methods, in the presence or absence of 1 µM apelin and 10 µM of LY294002, an 
inhibitor of the PI3K/Akt pathway. LY294002 was present in preincubation and 
flux media. Apelin was added to flux solution. (B) Apelin-mediated activation of 
KCC occurs through a MAPK dependent pathway in synthetic VSMC. KCC-
mediated Rb+ uptake by 24h-serum-deprived synthetic VSMCs was measured in 
the presence or absence of 1 µM apelin and 10 µM of PD98059, an inhibitor of 
the MAPK pathway, in preincubation and flux. For both (A) and (B), experimental 
outcomes were normalized to the baseline control. Data represents mean ± 
standard error of two independent experiments done in triplicates. For each 





Figure 33. Proposed signal transduction pathway of K-Cl cotransport 
regulation by apelin in contractile and synthetic VSMCs. Apelin binds to its 
receptor APJ and elicits three signaling pathways. Whereas oxLDL inhibits K-Cl 
cotransport activity, in contractile VSMCs, apelin uses the NO-mediated pathway 
to sustain this mode of cotransport. In synthetic VSMCs, apelin uses the 
PI3K/Akt and MAPK-mediated pathways to activate K-Cl cotransport activity. The 






Chronic treatment with apelin does not change K-Cl cotransport activity in 
serum-starved VSMCs 
Once we showed that acute treatment of apelin resulted in stimulation of K-Cl 
cotransport activity, we wondered if longer incubation times had the same effect. 
To this end, apelin was added to growth media before the flux time periods. As 
can be seen in Figure 34, serum-starved VSMCs were treated with 1 µM apelin 
for: 30 min, 1 h, 6 h, 12 h, 18 h or 24 h. Cells were rinsed thoroughly with BSS 
and K-Cl cotransport was compared to untreated cells (see Materials and 
Methods). As shown in Figure 34, no significance change in Rb+ flux was 
observed between untreated and apelin-treated VSMCs. To rule out the 
possibility that lack of effect on KCC activity was due to apelin degradation, 
MALDI-TOF mass spectrometry analyses were carried out with the assistance of 
Dr. David Cool. After apelin reconstitution in deionized water at 50 microgram 
final stock concentration, and over one year of storage, no evidence for 
proteolysis was detectable. As seen in Figure 35, three peaks at monoisotropic 
mass of 1532, 1555 and 1578 corresponding to apelin and sodium adducts 





Figure 34. Time-course of chronic apelin incubation on K-Cl cotransport. 
Cells serum-deprived for 24 h were exposed to 1µM apelin during different time 
periods.  After termination of apelin incubation, cells were washed 3 times with 
BSS solution and the flux experiment was carried out as described in Materials 
and Methods. Apelin was not present during the flux time. Ouabain (2 mM) and 
bumetanide (2 µM) were present during both the preincubation and flux. After 10 
min of Rb+ flux, no difference in KCC activity was observed between untreated 
(filled squares) and apelin-treated VSMCs (filled circles). Data shown is mean ± 
standard error of a representative experiment done in triplicates. For each 









Figure 35. Mass spectrometry of water reconstituted apelin.  Apelin, 50 
micrograms, was mixed 1:1 with CHCA matrix and 1 microliter was spotted to a 
MALDI brushed steel plate.  A Bruker Autoflex III MALDI-TOF was used to 
capture the data with laser intensity settings adjusted at 70%, gain to 4.0 and 
3000 laser shots captured randomly around the spot. The data represent the 




SPECIFIC AIM 3 
 
To assess the factors, such as, serum, osmolality, ionic strength, VSMCs 
phenotypes on apelin-mediated effect on K-Cl cotransport activity. The 
above factors will shed light on possible variability of the response of K-Cl 




RESULTS: Specific Aim 3  
Factors affecting apelin response: Variable effects on K-Cl cotransport 
activity.  
During the determination of K-Cl cotransport activity, variability in the extent of 
activation after apelin treatment became evident. Being aware of several factors, 
such as the effect of serum deprivation, extracellular ionic content and 
osmolalities as determinants for changes in K-Cl cotransport, we determined 
whether serum deprivation and/or sodium-free media altered the apelin-mediated 
Rb+ response in VSMCs (150, 182).  
 
As shown in Figure 36 (A and B), the absence of extracellular Na+ prevented the 
apelin-mediated increase in K-Cl cotransport activity irrespective of serum 
deprivation, cell phenotype (synthetic and contractile) and extracellular 
osmolality. In addition, neither hypotonic incubation (known to activate K-Cl 
cotransport) nor apelin treatment resulted in changes in Rb+ influx levels under 
these conditions. Furthermore, previously described inhibitory stimuli, such as, 
hypertonicity resulted in no change in K-Cl cotransport activity and similarly, 
apelin treatment had no effect in Rb+ influx.  To date, the role of extracelluar Na+ 
in sustaining KCC activity and regulation remains unclear.  
 
To further dissect the variability behind the apelin-mediated effect on K-Cl 




synthetic VSMCs was tested.  As shown in Figure 37, the addition of external 
Na+ did not sustain the previously shown apelin-mediated increase of Rb+ influx. 
In contrast, the combination of serum and extracellular Na+ allowed apelin to 
potentiate the K-Cl cotransport under hypotonicity and hypertonicity. Surprisingly, 
under isotonic conditions, apelin treatment did not result in changes of baseline 










Figure 36. Effect of apelin on KCC activity in primary cultures of rat aortic 
vascular smooth muscle cells (VSMCs) with respect to various osmolalities 
in the absence of Na+ and serum. Panel (A) Synthetic VSMCs (passage 39), 
and Panel (B) Contractile VSMCs (passage 3). Rb+ influx was determined from 
serum-starved cells at different osmolalities in Na+-free solutions. Osmolality 
changes were achieved by adding NMDGCl and NMDGSf. Ouabain (2 mM) and 
bumetanide (2 µM) were present in preincubation and flux solution. Apelin (1 µM) 
was added during flux. The difference between Rb+ influx in NMDGCl and 
NMDGSf was used to determine Na+-independent KCC activity. Data represents 













Figure 37. Effect of apelin on KCC activity with respect to various 
osmolalities in serum-starved and serum-fed VSMCs in the presence of 
external Na+.  KCC activity was measured from serum-starved and serum-fed 
(24 h) VSMCs (passage 11) in the presence of external Na+ at different 
osmolalities (Panel A and B). NaCl and NaSf were used to increase the 
osmolality. Cells were exposed to various tonicities in the preincubation and flux 
media containing ouabain (2 mM) and bumetanide (5 µM). Apelin (1 µM) was 
added during flux. As shown in Panel (A) apelin treatment did not change KCC 
activity in serum-starved cells. In Panel (B) apelin treatment significantly 
increased KCC activity under hypo and hypertonicity. Data shown are mean ± 




Since incomplete inhibition of alternative K+/Rb+ transport mechanisms such as, 
the ouabain-sensitive Na+/K+ pump and/or bumetanide-sensitive Na+-K+-2Cl- 
cotransporter could be responsible for the apparent lack of apelin effect under 
isotonic conditions, we performed dose-response curves to rule out the possibility 
of residual Rb+ transport with ouabain (2 mM) and bumetanide (2-5 µM) 
concentrations used so far. As shown in Figure 38, ouabain (2 mM) resulted in 
complete inhibition of the Na+/K+ pump. Addition of ouabain to the preincubation 
media did not result in any further inhibition of the ouabain-sensitive Rb+ 
transport compared to the one observed during flux incubation period. As seen in 
Figures 39A-C, residual K+/Rb+ transport was detectable at 2 µM bumetanide. 
Therefore, higher bumetanide concentrations (up to 30 µM) will be required to 
fully inhibit Na+-K+-2Cl- cotransport activity in subsequent Rb+ influx 
determinations.  
 
Having determined the requirement of extracellular Na+ and presence of serum in 
the growth media for the apelin-mediated increase in K-Cl cotransport, we 
reevaluated the osmolality-dependency of Rb+ fluxes in VSMCs using 30 µM 
bumetanide (Figure 40). To our surprise, extracellular Na+ was required for K-Cl 
cotransport to be activated and inhibited under hypotonicity and hypertonicity, 
respectively (Figure 40A). Presence of extracellular Na+ and serum in the growth 
media resulted in activation and inhibition of K-Cl cotransport under hypo- and 
hypertonic conditions, respectively (Figure 40B). Simultaneous K-Cl cotransport 
inhibition and activation of Na+-K+-2Cl- mechanisms during increases in 




necessary to properly control cell volume (Figure 41).  To further confirm the 
coordinated activity of K+ transport mechanisms (K-Cl cotransport vs. Na+-K+-2Cl-
); Na+-K+-2Cl- activity was assessed under the same conditions. As shown in 
Figure 41A, whereas increases in osmolality inhibited K-Cl cotransport, opposite 
regulation (activation) of Na+-K+-2Cl- was observed (Figure 41B). In other words, 
presence of extracellular Na+ and serum in the growth media resulted in the 
expected activation of K-Cl and possibly inhibition of Na+-K+-2Cl- (Figure 41A 
and B). These results highlight the coordinate activity of cation chloride 
cotransporters (CCCs) to modulate intracellular Cl- concentration and therefore 





Figure 38. Ouabain dose-reponse curve. KCC activity was measured in 
isotonic condition in the presence of increasing concentration of ouabain ranging 
from 0-2 mM and in the presence of 5 µM bumetanide to inhibit Na+-K+-2Cl- 
cotransporter. Cl--dependent Rb+ influx (KCC) became stable by 2 mM ouabain 
and there was no difference in KCC activity when ouabain was present in flux 
(filled black squares) vs. preincubation and flux (filled red circles) at highest 
concentration used. Data represents mean ± standard error of a representative 






Figure 39. Bumetanide dose-response with respect to various osmolalities.  
Panel (A) Hypotonic conditions, Panel (B) Isotonic condition, and Panel (C) 
Hypertonic condition. NaCl and NaSf salts were used to increase the tonicity of 
external media. Confluent VSMCs were washed three times with BSS and flux 
experiment was carried out as described in Materials and Methods. Cl--
dependent Rb+ influx, KCC, activity was assessed in the presence of bumetanide 
concentration ranging from 0-50 µM (present during preincubation + flux).  
Ouabain (2 mM) was present to inhibit the Na+/K+ pump. Flux was performed at 5 
min and 20 min time period. The Rb+ influx in Cl- was subtracted from that in Sf- 
media to yield the Cl--dependent Rb+ influx. Data represent mean ± error of three 










Figure 40. External Na+ influences KCC sensitivity to osmoregulation. 
Serum-fed VSMCs were fluxed in the absence (Panel A) or presence (Panel B) 
of external Na+ at different osmolalities. Changes in osmolality from solutions 
containing Na+ were achieved by using NaCl and NaSf, whereas NMDGCl and 
NMDGSf were used for Na+-free media. Ouabain (2 mM) and bumetanide (30 
µM) was used to inhibit Na+/K+ pump and Na+-K+-2Cl+. As shown in Panel B, 
KCC activity is differentially regulated according to changes in osmolality. In 
contrast, in Na+-free media (Panel A), KCC activity was unresponsive to changes 
in osmolality. Data represents mean ± standard error of a representative 










Figure 41. NKCC and KCC activation tightly and reciprocally regulated 
(Yin-Yang mechanism). To establish Yin-Yang canonical mechanism between 
NKCC and KCC along different tonicities (NaCl and NaSf were used to increase 
the tonicity of external media). VSMCs were grown in serum enriched media until 
subconfluency and Rb+ influx was tested in the presence of external Na+, and 
ouabain (2 mM) and bumetanide (30 µM) was used in preincubation and flux. 







Apelin effect on K-Cl cotransport in serum-fed VSMCs under different 
osmolalities.  
To further dissect the mechanism(s) behind the apelin-mediated increase in K-Cl 
cotransport, we treated subconfluent serum-fed VSMCs with apelin at different 
osmolalites by either modifying the ionic strength or keeping it constant (addition 
of sucrose). In previous Figures 29 to 37A, VSMCs were serum deprived for 24 
h before being exposed to apelin. This time, Rb+ influx was measured in apelin-
treated VSMCs that were grown in serum containing media. Under constant ionic 
strength where sucrose was used to increase the extracellular osmolalities, the 
apelin response was not detectable (Figure 42). Thus, subsequent experiments 
were conducted under variable ionic strength conditions which resemble 
physiological challenges in vivo. To shed light into the mechanism(s) behind the 
lack of apelin effect under isotonic condition tested under 5 µM bumetanide 
(Figure 37B), 30 µM bumetanide was used on contractile VSMCs at different 
osmolalities obtained by modifying ionic strength. As shown in Figure 43, apelin 
treatment allowed increases in K-Cl cotransport in hypo- and hypertonic 
conditions. Interestingly, the extent of activation was considerably less when 
compared to synthetic VSMCs (Figure 37B vs 43). These results suggest that 
heterogeneous cultures of synthetic VSMCs might be unresponsive to apelin 
when cell integrity is not compromised by changes in osmolality (isotonic 
conditions). When similar assays were carried out using contractile VSMCs 
(Figure 43) a major difference in the apelin-mediated effect was observed. Under 




stimulated by apelin treatment. Altogether these results suggest that contractile 
VSMCs under isotonic conditions might be more susceptible to apelin effects. 
These findings are in accordance with a more pronounced need in the 
responsiveness to apelin from contractile/healthy VSMCs to aid in the repair of 







Figure 42. Effect of apelin in constant ionic strength. In serum-fed contractile 
(Panel A) and synthetic (Panel B) cells, KCC activity was measured in the 
presence or absence of apelin at different osmolalities. Sucrose was used to 
change the osmolality of the flux solution while keeping the concentration of other 
salts constant. As can be seen, apelin treatment did not change KCC activity 
under this condition. Data represents mean ± standard error of two independent 







Figure 43. Effect of apelin on KCC activity in serum-fed contractile cells 
with respect to increase in external osmolality. Contractile VSMCs (passage 
3) were grown in serum enriched media until subconfluency. Cells were then 
washed and exposed to different osmolalities (Hypotonic: 120 mOSM, Isotonic: 
300 mOSM and Hypertonic: 450 mOSM) in the preincubation and flux media 
containing ouabain (2 mM) and bumetanide (30 µM).  NaCl and NaSf salts were 
used to change the osmolalities of the external media. For each condition, n = 3 




Apelin effect on K-Cl cotransport activity in synthetic VSMCs at different 
time point under hypotonic conditions  
We then evaluated the kinetics of the effect of apelin in hypotonic conditions on 
K-Cl cotransport activity. VSMCs were grown until subconfluency in serum rich 
media and then apelin was added for 30 minutes, 1 hour, 12 hours, 18 hours and 
24 hours before flux.  Cells were then exposed to hypotonic media and Cl--
dependent Rb+ influx was measured for 20 min in the presence of 1 µM apelin. 
As shown in Figure 44; apelin treatment resulted in significant increases on K-Cl 
cotransport at most time points tested. Interestingly, after 24 h of 1 µM apelin 
incubation; no significant increase in K-Cl cotransport was detected. It is possible 
that long exposure times result in APJ desensitization (internalization) and 
therefore absence of apelin effect on K-Cl cotransport activity. GPCRs like APJ 
can be desensitized following activation by agonists through phosphorylation by 
members of the GRKs (G-protein coupled receptor kinases (196). This mode of 







Figure 44. Effect of apelin in hypotonic conditions at different time points. 
Subconfluent VSMCs were incubated in the presence of 1 µM apelin for 30 min, 
1 hour, 12 hours, 18 hours and 24 hours in a serum enriched growth media. Cells 
were then washed with BSS solution and flux measurement was carried out 
under hypotonic conditions in the presence of Ouabain (2 mM) and bumetanide 
(30 µM) to inhibit the pump and Na+-K+-2Cl- cotransport activity as described in 
MATERIALS AND METHODS. Apelin was added for additional 20 min during flux 
to the treatment groups. Each experimental outcome was normalized to its 
control. Apelin treatment resulted in significant increases of K-Cl cotransport 
activity in all time points tested except 24 hours. It is possible that APJ 
desensitization at 24 h could be the reason of absence of apelin stimulatory 






Apelin regulatory effect on K-Cl cotransport activity during changes in 
osmolality in serum-fed synthetic phenotypes 
VSMCs of synthetic passages are implicated in atherosclerosis. Thus, to assess 
apelin-induced K-Cl cotransport activity, VSMCs of various synthetic passages 
were examined. Urged by the observation that K-Cl cotransport could still be 
stimulated by apelin under hypertonic conditions (in which basal KCC activity is 
normally abrogated) (Figure 37B and 43) (91, 111), we examined whether 
manipulation of cell volume by shrinking and swelling could result in differences 
in the apelin response. Although we did not measure cell volume in our study, we 
did modulate external osmolality which would produce similar changes in cellular 
volume. Figure 45 shows various conditions where apelin effects were tested 
during: a) cell swelling (hypotonicity), b) shrinkage (hypertonicity), c) shrinkage 
followed by swelling or d) swelling followed by shrinkage.  
 
As can be seen in Figure 45A, under hypotonic conditions/cell swelling, apelin 
treatment further enhanced the activation of K-Cl cotransport by 54 % (*p < 0.05).  
Importantly, osmolarity shifts from hypertonicity to hypotonicity (shrinkage 
followed by swelling) did not affect the apelin stimulatory effect (74 % increase,   
**p < 0.01) on KCC activity.  These findings strongly suggest that apelin might 
potentiate regulatory volume decrease (RVD) mechanisms. When preswollen 
VSMCs were shrunken by shifting them from hypotonicity to hypertonicity 
(swelling followed by shrinkage); apelin treatment failed to stimulate KCC activity 
(Figure 45B). Next we established whether VSMCs’ progression to late synthetic 




hypertonicity to hypotonicity. As shown in Figure 46A, the apelin stimulatory 
effect was stronger in early synthetic VSMCs (passage number 7) when 
compared to later states (passage number 13 and 20). Similarly, and in 
accordance with Figure 45B; when pre-swollen VSMCs from different passage 
numbers were shifted to hypertonicity, apelin treatment failed to promote K-Cl 
cotransport (Figure 46B). The summaries of apelin response from contractile 










Figure 45. Apelin enhances KCC sensitivity with changes in external 
osmolality. KCC-mediated Rb+ influx was measured in synthetic serum-fed 
VSMCs (passage 7). Cells were grown in serum enriched media and after 
reaching sub confluence, apelin was added for 6 h in the treatment group. Apelin 
was added for additional 20 min during flux; whereas, the control group 
contained no apelin. Panel (A). Apelin stimulated KCC activity in hypotonic 
condition (120 mOSM) and also in preshrunken cells that were first exposed to 
hypertonic solution (450 mOSM) during preincubation (10 min) and then in 
hypotonic solution (120 mOSM) during flux (20 min). Panel (B) Apelin stimulated 
KCC activity (borderline significant) under hypertonic conditions (450 mOSM) but 
lack of apelin response was observed in pre-swollen cells when the cells were 
transferred from hypotonic (120 mOSM) to hypertonic conditions (450 mOSM). 











Figure 46. Apelin response in preshrunken cells is passage-dependent and 
absent in preswollen cells. Cells were grown in serum enriched media and 
after reaching sub confluence, apelin was added for 6 h in the treatment group. 
Furthermore, apelin was present for additional 20 min during flux; whereas, the 
control group contained no apelin. Panel (A) Percent (%) apelin-mediated 
increase in KCC activity in pre-shrunken cells subsequently swollen (cells that 
were first exposed to hypertonic solution during preincubation (10 min) and then 
in hypotonic solution (20 min) during flux (450  120 mOSM), and Panel (B) 
Percent (%) apelin-mediated increase or decrease in KCC activity in pre-swollen 
cells subsequently shrunken (cells that were first exposed to hypotonic solution 
during preincubation and then in hypertonic solution during flux (120  450 
mOSM). For each VSMCs passage, apelin response was normalized to that of 
the control. Data represents mean ± standard error of three independent 






Table 3. Summary of apelin effect on K-Cl cotransport in VSMCs. Under 
isotonic conditions, acute treatment of apelin-13 in serum-starved VSMCs 
stimulated KCC activity in the presence of extracellular sodium. In the absence of 
serum deprivation (serum-fed cells) apelin-13 treatment significantly increased K-
Cl cotransport in contractile VSMCs. In contrast, in synthetic VSMCs, apelin-13 
did not promote KCC activity under isotonic conditions. Similarly, in the absence 
of extracellular sodium no stimulatory effect of apelin was observed. Stimulation 
of K-Cl cotransport activity can be observed in serum-fed synthetic VSMCs under 




of activation was not seen at longer incubation times (24 h) probably due to APJ 
desensitization. Finally, KCC activity from serum-fed synthetic VSMCs was up 
regulated when cells were transferred from hypertonic to hypotonic conditions. 
Importantly, apelin stimulated KCC activity only when apelin was present in the 
flux media (acute activation); no stimulation of K-Cl cotransport was seen after 






Figure 47. Schematic hypothetical representation of apelin regulation of K-
Cl cotransport in VSMCs. In VSMCs, the binding of apelin-13 to its receptor 
APJ, activates K-Cl cotransport by increasing KCC protein expression and 
possibly increased membrane trafficking (1). Additionally, apelin-13 elicits the 
activation of several signaling cascades including PI3K/Akt, NO/cGMP/PKG1 and 
ERK1/2 to sustain KCC activation (2). Apelin-13-mediated activation of KCC 
occurs under both, hypertonicity and hypotonicity. In normal conditions, 
hypotonicity and RVD stimulate K-Cl cotransport through activation of protein 
phosphatases like PP1 and PP2A. It is possible that apelin administration results 
in PP1 and PP2A stimulation in order to sustain KCC activation (4). During 
hypertonicity, KCC activity is inhibited by phosphorylation events and activation 




mediated activation of K-Cl cotransport is dependent on the presence of serum in 
the growth media, ionic strength and is central to control cell proliferation and 
migration which are required to sustain VSMCs phenotypic switching. 
Importantly, apelin-13 administration is able to rescue the oxLDL mediated 




DISCUSSION: Specific Aims 2 and 3 
Apelin/APJ has emerged as an important regulator of cellular homeostasis and 
cardiovascular function. By targeting apelin/APJ, and subsequent stimulation of 
several signaling cascades such as the NO/cGMP/PKG, PI3K/Akt and ERK (1/2), 
a coordinated cardio-protective multicellular response takes place to repair and 
prevent further cell damage (53, 63, 197-199). Migration of VSMCs and their 
transition from contractile to synthetic states constitute initial steps to aid in the 
repair of atherosclerotic endothelium. Failure of VSMCs to switch back to 
contractile states accelerates lesion formation and results counterproductive due 
to possible increases in inflammatory processes (29). Although, further research 
is required to fully understand the inability of VSMCs to return to contractile 
states, in general, it has become evident that dysregulations in cell proliferation 
(mostly caused by high levels of growth factors, and uncontrolled uptake of 
oxLDL) are involved in the molecular pathogenesis of atherosclerosis (42, 47).  
 
Several lines of evidence have pointed out that common signaling networks 
regulate the activity of KCC and the apelin-mediated cardio-protective effects 
(53, 105, 150, 157, 160, 184). Here we have provided evidence to support that 
electroneutral K-Cl cotransport in VSMCs is responsive to apelin via its 
membrane receptor APJ. Although differences were found in the APJ subcellular 




 VSMCs (perinuclear, localization), in general, the apelin receptor was found 
abundantly expressed in contractile and synthetic VSMCs (Figure 28C-D). 
Apelin treatment stimulated K-Cl cotransport irrespective of VSMCs phenotype. 
These results suggest a rapid trafficking of APJ to the membrane in order to elicit 
a comparable response in synthetic and contractile VSMCs.  Although further 
experiments will be required to determine whether apelin could change the APJ 
subcellular localization, it is likely that increased APJ membrane trafficking 
facilitates apelin signaling in VSMCs (200, 201).  In addition, further research will 
be required to confirm whether APJ is present in endosomes or any other 
subcellular compartment (202).  
 
Our results also indicate an intricate overlap among several signaling cascades 
(NO/cGMP/PKG, PI3K/Akt and ERK1/2) to coordinate the apelin-mediated 
effects on KCC activity. Although selective inhibition of PKG, Akt and ERK1/2 
completely prevented the apelin stimulatory-effect on the K-Cl cotransport in 
VSMCs (Figures 31-32); further examination will be required to determine the 
exact degree of contribution of each signaling cascade and their relevance to 
sustain vascular tone and endothelial function in vivo. Based on previous studies 
by our laboratory and others, in which PKG expression has proven to be absent 
in synthetic VSMCs (132), it is possible that differential regulation of KCCs’ 
activity might occur within VSMCs phenotypes. Contractile VSMCs could be 
more dependent on the NO/cGMP/PKG pathway to respond to apelin, whereas 
in synthetic VSMCs, apelin could elicit its effects mostly through PI3K/Akt and 




results in an increase of KCCs expression/turnover, more efficiently trafficking to 
the plasma membrane or posttranslational modifications that promote an 
increase in KCCs activity. For years it has been recognized that 
phosphorylation/dephosphorylation events greatly determine the activity of 
NKCCs and KCCs. Consistent with their coordinated role in modulating 
intracellular chloride concentration, reciprocal modes of activation govern their 
activity. Increased activity of serine threonine kinases such as members of the 
WNK family (WNK 1-4) and Ste20 (SPAK and OSR1) enhance NKCCs activity 
and decrease KCCs function. Similarly, up regulation of protein phosphatases 
(PP1 and PP2B) inhibit NKCCs and activate KCCs. Therefore, it is likely that 
dephosphorylation of serine and threonine residues within the KCCs carboxy 
terminus constitute final events in the apelin stimulatory effect on KCCs (146).  
 
Studies have shown that apelin and oxLDL have opposite effects on 
cardiovascular function. In CVD low levels of circulating apelin have been 
observed (203). Similarly, it has been recently shown that low plasma apelin 
concentrations constitute a risk to develop atrial fibrillation (204). Even though 
atherosclerosis is caused and sustained by a plethora of factors, the increasing 
evidence pointing out apelin administration as a remarkable protective therapy 
against atherosclerotic lesions is fully supported by our observations. Here we 
showed that apelin treatment restored the oxLDL-inhibitory effect on KCCs 
activity in contractile VSMCs (Figure 31B). Since high levels of oxLDL have 
shown in one hand to promote an increase in KCC1 mRNA expression (166) and 




escaped our notice that the increased mRNA levels for KCC could be part of a 
compensatory mechanism to attempt restore VSMCs’ migration and normal cell 
volume.  
Perhaps the most intriguing findings in these studies constitute the variability in 
the apelin-mediated effect on K-Cl cotransport. These differences were related to 
changes in external Na+, serum and phenotypic states. In summary, serum-fed 
cells in the presence of external Na+ displayed activation of K-Cl cotransport 
under hypo- and hypertonic conditions. In the absence of extracellular Na+, no 
stimulatory effect by apelin was observed. To date it remains to be determined 
how extracellular Na+ could be modulating the originally described sodium 
independent K-Cl cotransport. 
 
Additionally, our data highlights apelin’s role to modulate KCC activity in 
response to changes in extracellular osmolality (Figures 37B, 43-45). In both, 
synthetic and contractile VSMCs, apelin treatment resulted in further stimulation 
under hypotonic/swelling conditions (Figure 37B and 43-44). Studies have 
shown that hypotonic stimuli result in cell swelling and decreased lumen 
diameters (205). Noteworthy, hypotonic conditions also promote KCC activation; 
all of the above highlights increase in KCC activity as responsible for the apelin-
mediated cardioprotective effects. The above has clinical implications since 
increased K-Cl cotransport and therefore vasorelaxation are commonly seen 
after exposure to hydralazine (HYZ), a vasodilator that has been shown to 
reduce tension of the vascular smooth muscle through increase in K-Cl 




response under hypotonic stimuli in VSMCs. Altogether our findings highlight 
increases in KCC activity as important effectors in sustaining normal vascular 
tone. 
Under hypertonic/shrinking conditions, apelin treatment significantly increased 
KCCs activity and bypassed the osmolality-mediated inhibition of KCCs in 
synthetic VSMCs (Figure 37B). To our knowledge, this is the first time an 
extracellular stimulus bypasses the osmolality-mediated regulation on KCCs 
activity. Studies have shown that cell shrinkage results in increased lumen 
diameters and thus, stimulation of apelin response in hypertonic condition might 
be beneficial in maintenance of vessel relaxation in vivo (206). Consistently, 
absence of stimulation by apelin was observed when pre-swollen VSMCs were 
exposed to hypertonic media (shifted from 120 to 450 mOSM). In contrast, when 
pre-shrunken VSMCs were exposed to hypotonic stimuli (shifted from 450 to 120 
mOSM); apelin treatment resulted in significant increase of KCCs. Based on 
published reports, it is likely that serine and threonine residues within KCCs 
carboxy terminus constitute final targets in the apelin stimulatory effect on KCCs 
(146, 207). Altogether these findings place apelin as a master regulator of cell 
volume and highlight its role during osmosensing processes.  
 
KCC is involved in ionic balance and cellular homeostasis. Apelin and its 
receptor are also implicated in fluid homeostasis (52, 64, 72). The mechanisms 
by which apelin promotes fluid and cellular homeostasis by regulating ion 
transporters are less understood. Thus, the third specific aim of the thesis sought 




action on KCC and by modulating its transport activity. This homeostatic 
mechanism is important for overall vascular function. Finally, the close 
association between cell proliferation and volume regulation suggests that K-Cl 
cotransport activity and its regulation by apelin, are both important to confer 
protection against atherosclerosis. A better understanding of apelin effects on K-
Cl cotransport will help design a more powerful therapeutic approach to treat 





The work presented in this thesis offers compelling evidence supporting that 
apelin/APJ constitutes an important modulator of electroneutral K-Cl cotransport 
in rat aortic vascular smooth muscle cells. Increased K-Cl cotransport activity, 
measured by atomic absorption spectrometry, was determined under isotonic 
condition, in both contractile and synthetic VSMCs when exposed to 1 µM of the 
most abundant form of apelin found in the circulatory system (apelin-13). In 
contrast, no stimulatory effect on K-Cl cotransport was observed when apelin 
was present in serum-free growth media before flux measurements. 
 
By using selective inhibitors of PKG, PI3K and MAPK signaling pathways, such 
as KT5823, LY294002, and PD98059, we demonstrated that under isotonic 
conditions, apelin-13 increased K-Cl cotransport in serum-starved VSMCs 
through activation of those signaling cascades. Our data also suggests 
differences in expression and subcellular localization of APJ among VSMCs 
phenotypes. APJ total expression was decreased in synthetic VSMCs. Its 
expression appeared more diffused and cytoplasmic when compared to 
contractile VSMCs where a more localized and perinuclear immunolocalization 
could be observed.  
 
We showed that K-Cl cotransport in VSMCs is dramatically impaired (~ 70 % of 




progression. Importantly, apelin treatment prevented the oxLDL-mediated 
inhibition of K-Cl cotransport since similar activation was observed in response to 
apelin. These findings are in accordance with the protective roles of apelin 
against cardiovascular disease (CVD). 
 
However, variability in the apelin response was observed among VSMCs 
phenotypes. K-Cl cotransport activity is more prone to activation by apelin in 
serum-fed compared to serum-starved VSMCs. Besides, extracellular sodium 
was required for apelin to modulate KCC activity. Additionally, apelin’s role in 
controlling K-Cl cotransport proved to be of central importance since stimulation 
of KCC activity was enhanced under hypotonic and hypertonic conditions. Similar 
stimulatory effect of apelin was observed when pre-shrunken VSMCs were 
swollen. In sum, these results highlight apelin’s role in controlling cellular 
homeostasis and place KCC activity as an important therapeutic target) and 
potential mediator in the apelin-conferred protection against CVD.  
 
In addition, we found that expression levels of cytoskeletal protein markers like α-
actin, vimentin, and desmin decreased in late synthetic stages. Finally we also 
showed that both, the apparent Rb+ and Cl- affinities and Vmax values of KCC 
increased in late synthetic VSMCs compared to earlier states. Consistently, 
increased protein expression of KCC1 and KCC4 were observed in late synthetic 
VSMCs compared to earlier states. These results point out that the functional 
properties of KCC may be involved and required to sustain VSMCs phenotypic 
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